

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (

New England Journal of Medicine

385, 585-594

DOI: [10.1056/nejmoa2108891](https://doi.org/10.1056/nejmoa2108891)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccine in Indian children: A debatable issue!! Journal of Marine Medical Society, 2021, .	0.0	0
2	Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 ⁺ T-Cell Responses. SSRN Electronic Journal, 0, , .	0.4	0
3	Strategies to decrease COVID-19 vaccine hesitancy for children. Journal of Pharmaceutical Health Services Research, 2021, 12, 539-544.	0.3	8
4	The SARS-CoV-2 B.1.618 variant slightly alters the spike RBD's ACE2 binding affinity and is an antibody escaping variant: a computational structural perspective. RSC Advances, 2021, 11, 30132-30147.	1.7	57
6	The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. Journal of Infectious Diseases, 2022, 225, 934-937.	1.9	3
7	Reducing Childhood Immunization to Scale Up COVID-19 Immunization in Low- and Lower Middle-Income Countries: Impact on Under-Five Mortality. SSRN Electronic Journal, 0, , .	0.4	1
9	Reactogenicity and Immunogenicity of Heterologous ChAdOx1-nCoV19 and BNT162b2 Vaccination: A Systematic Review and Meta-Analysis of the Heterologous COVID-19 Vaccination Outcomes. SSRN Electronic Journal, 0, , .	0.4	1
10	Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune Escape. SSRN Electronic Journal, 0, , .	0.4	0
16	Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study. JMIR Research Protocols, 2021, 10, e30259.	0.5	8
23	Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet, The, 2021, 397, 2331-2333.	6.3	490
28	SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet, The, 2021, 397, 2461-2462.	6.3	882
33	Human vaccines & immunotherapeutics: news. Human Vaccines and Immunotherapeutics, 2024, 17, 4703-4704.	1.4	1
34	Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet, The, 2021, 398, 385-387.	6.3	366
36	SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. Journal of Evolutionary Biology, 2021, 34, 1867-1877.	0.8	29
37	Human Vaccines & Immunotherapeutics: News. Human Vaccines and Immunotherapeutics, 2021, 17, 3841-3842.	1.4	0
38	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Reviews in Medical Virology, 2022, 32, e2277.	3.9	57
39	COVID vaccines slash viral spread " but Delta is an unknown. Nature, 2021, 596, 17-18.	13.7	32
40	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. Infection, 2022, 50, 11-25.	2.3	50

#	ARTICLE	IF	CITATIONS
42	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
44	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. <i>Lancet</i> , The, 2021, 398, 207-209.	6.3	112
45	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. <i>Current Biology</i> , 2021, 31, R918-R929.	1.8	246
46	An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	50
48	COVID-19 vaccines: what do we know so far?. <i>FEBS Journal</i> , 2021, 288, 4996-5009.	2.2	7
50	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
51	Children should be offered vaccination against COVID-19. <i>LymphoSign Journal</i> , 0, , .	0.1	0
52	Graphene, Carbon Nanotube and Plasmonic Nanosensors for Detection of Viral Pathogens: Opportunities for Rapid Testing in Pandemics like COVID-19. <i>Frontiers in Nanotechnology</i> , 2021, 3, .	2.4	17
53	Optimal COVID-19 Vaccine Sharing Between Two Nations That Also Have Extensive Travel Exchanges. <i>Frontiers in Public Health</i> , 2021, 9, 633144.	1.3	4
54	Which are the best coronavirus disease 2019 vaccines?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1729-1732.	2.8	2
55	Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 148-157.	0.3	83
58	Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada. <i>Vaccine</i> , 2021, 39, 7300-7307.	1.7	13
66	Living with COVID-19: The road ahead. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 619-628.	0.2	8
67	While we are discussing the SARS-CoV-2 virus laughs. <i>Journal of Medical Virology</i> , 2021, 93, 6475-6476.	2.5	3
71	SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status – Los Angeles County, California, May 1–July 25, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1170-1176.	9.0	107
73	SARS-CoV-2 immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January–March 2021. <i>Epidemiology and Infection</i> , 2021, 149, e239.	1.0	4
74	Vaccine Effectiveness Studies in the Field. <i>New England Journal of Medicine</i> , 2021, 385, 650-651.	13.9	58
76	New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status – New York, May 25–July 25, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1150-1155.	9.0	179

#	ARTICLE	IF	CITATIONS
78	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
79	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2455-2456.	4.8	35
83	Update on human genetic susceptibility to COVID-19: susceptibility to virus and response. <i>Human Genomics</i> , 2021, 15, 57.	1.4	15
84	Immune thrombocytopenia: vaccination does not equal causation. <i>Haematologica</i> , 2021, , .	1.7	0
85	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 35-42.	4.6	612
88	ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections. <i>European Journal of Internal Medicine</i> , 2021, 93, 112-113.	1.0	23
89	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus diseaseâ€”19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
90	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNeâ€”short- And long-term Immune reSponSe evAluation in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	1.4	18
91	Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9131.	1.8	68
92	Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant â€” Mesa County, Colorado, Aprilâ€”June 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1084-1087.	9.0	60
93	COVID-19 boosters in rich nations will delay vaccines for all. <i>Nature Medicine</i> , 2021, 27, 1659-1660.	15.2	17
95	Real world effectiveness of covid-19 vaccines. <i>BMJ</i> , The, 0, , n2034.	3.0	10
97	Lessons from COVIDâ€”19: A reflection on the strengths and weakness of early consensus recommendations for pediatric difficult airway management during a respiratory viral pandemic using a modified Delphi method. <i>Paediatric Anaesthesia</i> , 2021, 31, 1074-1088.	0.6	4
98	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). <i>Clinical Infectious Diseases</i> , 2022, 75, e1128-e1136.	2.9	323
100	Evolutionary trajectory of SARS-CoV-2 and emerging variants. <i>Virology Journal</i> , 2021, 18, 166.	1.4	105
101	Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 2-3.	4.6	9
103	Rapid Global Spread of the SARS-CoV-2 Delta (B.1.617.2) Variant: Spatiotemporal Variation and Public Health Impact. <i>Zoonoses</i> , 2021, 1, .	0.5	18
104	The rapid adaptation of SARS-CoV-2â€”rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18

#	ARTICLE	IF	CITATIONS
106	Covid-19: Two vaccine doses are crucial for protection against delta, study finds. <i>BMJ, The</i> , 2021, 374, n2029.	3.0	10
108	COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series. <i>Medicina (Lithuania)</i> , 2021, 57, 891.	0.8	12
110	The future of COVID-19: A vaccine review. <i>Journal of Infection and Public Health</i> , 2021, 14, 1461-1465.	1.9	16
111	Breakthrough Infection among Fully Vaccinated Physicians Working in COVID-19 Treatment Centers; Prevalence, Presenting Symptoms, Co-Morbidities and Outcome in the Third Wave of Epidemics in Myanmar. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2021, 2, 721-730.	0.1	0
121	Effective COVID-19 Control: A Comparative Analysis of the Stringency and Timeliness of Government Responses in Asia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8686.	1.2	18
122	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
123	Herd immunity: challenges and the way forward in Korea. <i>Epidemiology and Health</i> , 2021, 43, e2021054.	0.8	4
124	Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. <i>MSphere</i> , 2021, 6, e0048021.	1.3	70
125	A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection. <i>Pathogens</i> , 2021, 10, 1078.	1.2	0
126	The macroeconomics of COVID-19 exit strategy: the case of Japan. <i>Japanese Economic Review</i> , 2021, 72, 651-682.	0.8	15
127	What we can learn from the dynamics of the 1889 "Russian flu" pandemic for the future trajectory of COVID-19. <i>Microbial Biotechnology</i> , 2021, 14, 2244-2253.	2.0	19
128	Covid-19: How many variants are there, and what do we know about them?: Video 1. <i>BMJ, The</i> , 2021, 374, n1971.	3.0	37
130	IMPACT OF VACCINATION ON COVID INFECTION IN HEALTH CARE WORKERS IN WESTERN ZONE OF INDIAN RAILWAYS. , 2021, , 31-34.		0
132	Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. <i>BMJ, The</i> , 2021, 374, n2015.	3.0	223
134	Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1110-1123.	1.9	26
135	To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1211-1220.	2.0	85
137	SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated. <i>Frontiers in Microbiology</i> , 2021, 12, 749634.	1.5	3
138	Potential recurrence of COVID-19 in a healthcare professional: SARS-CoV-2 genome sequencing confirms contagiousness after re-positivity. <i>International Journal of Infectious Diseases</i> , 2021, 112, 318-320.	1.5	2

#	ARTICLE	IF	CITATIONS
140	Human vaccines & immunotherapeutics news: July 2020. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 1-3.	1.4	0
141	Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. <i>Medical Journal of Australia</i> , 2021, 215, 427-432.	0.8	20
143	Evaluation and management of COVID-19-related severity in people with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002299.	1.2	12
145	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
146	Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. <i>Biomedicines</i> , 2021, 9, 1230.	1.4	8
147	The Importance of Context in Covid-19 Vaccine Safety. <i>New England Journal of Medicine</i> , 2021, 385, 1138-1140.	13.9	15
148	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
149	T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2554-2556.	4.8	72
150	A closer look at U.S COVID-19 vaccination rates and the emergence of new SARS-CoV-2 variants: It's never late to do the right thing. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102709.	0.5	4
151	The role of exercise in rehabilitation of discharged COVID-19 patients. <i>Sports Medicine and Health Science</i> , 2021, 3, 194-201.	0.7	14
152	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
154	Relationship Between COVID-19 Cases and Vaccination Rates in New York State Counties. <i>PRIMER (Leawood, Kan)</i> , 2021, 5, 35.	0.6	4
155	Association of the Delta (B.1.617.2) Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) With Pregnancy Outcomes. <i>Obstetrics and Gynecology</i> , 2021, 138, 838-841.	1.2	30
157	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
158	Vaccine nationalism and the dynamics and control of SARS-CoV-2. <i>Science</i> , 2021, 373, eabj7364.	6.0	80
159	Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School in Marin County, California, May-June 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1214-1219.	9.0	101
160	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , 2021, 9, 1964.	1.6	13
163	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <i>Nature Communications</i> , 2021, 12, 5407.	5.8	26

#	ARTICLE	IF	CITATIONS
164	Application of omics technology to combat the COVID-19 pandemic. <i>MedComm</i> , 2021, 2, 381-401.	3.1	11
165	Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. <i>Lancet Infectious Diseases</i> , 2022, 22, 43-55.	4.6	573
167	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
169	Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample. <i>Vaccines</i> , 2021, 9, 1010.	2.1	18
170	Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. <i>Nature Metabolism</i> , 2021, 3, 1466-1475.	5.1	76
172	Confronting the Delta Variant of SARS-CoV-2, Summer 2021. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1001.	3.8	167
173	Women's Lives Matter—The Critical Need for Women to Prioritize Optimal Physical Activity to Reduce COVID-19 Illness Risk and Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10271.	1.2	1
174	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
175	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. <i>Cell</i> , 2021, 184, 5077-5081.	13.5	114
176	SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters. <i>Viruses</i> , 2021, 13, 1773.	1.5	43
178	COVID-19 Vaccine Donations—Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review. <i>Vaccines</i> , 2021, 9, 1024.	2.1	52
179	Variants of SARS Coronavirus-2 and Their Potential Impact on the Future of the COVID-19 Pandemic. <i>Zoonoses</i> , 2021, 1, .	0.5	3
180	Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. <i>Frontiers in Immunology</i> , 2021, 12, 730051.	2.2	7
181	Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience. <i>Journal of Medical Virology</i> , 2022, 94, 287-290.	2.5	34
183	Risk assessment for COVID-19 transmission at household level in sub-Saharan Africa: evidence from DHS. <i>Genus</i> , 2021, 77, 24.	1.0	7
185	Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102814.	0.5	7
186	Ginkgolic Acid Inhibits Coronavirus Strain 229E Infection of Human Epithelial Lung Cells. <i>Pharmaceuticals</i> , 2021, 14, 980.	1.7	4
187	DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. <i>Expert Review of Vaccines</i> , 2021, 20, 1549-1560.	2.0	60

#	ARTICLE	IF	CITATIONS
188	Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years – United States, August 2020–August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1249-1254.	9.0	127
191	Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India. Journal of Medical Virology, 2022, 94, 407-412.	2.5	24
193	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 752003.	2.2	62
195	Forecasting the COVID-19 effects on energy poverty across EU member states. Energy Policy, 2022, 161, 112597.	4.2	37
196	Vaccines for COVID-19: Where do we stand in 2021?. Paediatric Respiratory Reviews, 2021, 39, 22-31.	1.2	53
199	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance, 2021, 26, .	3.9	48
203	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052.	2.1	22
205	Extracorporeal cardiopulmonary resuscitation: The need for high-quality research and the associated legal, ethical and pandemic-related challenges. Resuscitation, 2021, 169, 143-145.	1.3	3
209	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
212	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, .	3.2	16
213	The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. Environmental Chemistry Letters, 2022, 20, 1539-1544.	8.3	6
214	Positivity rate: an indicator for the spread of COVID-19. Current Medical Research and Opinion, 2021, 37, 2067-2076.	0.9	13
215	Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. New England Journal of Medicine, 2021, 385, 1330-1332.	13.9	150
216	Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Eurosurveillance, 2021, 26, .	3.9	54
219	Vaccination Diffusion and Incentive: Empirical Analysis of the US State of Michigan. Frontiers in Public Health, 2021, 9, 740367.	1.3	2
220	Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Affairs, 2021, 40, 1465-1472.	2.5	84
221	Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Eurosurveillance, 2021, 26, .	3.9	58
222	COVID-19 Vaccination Strategy in China: A Case Study. Epidemiologia, 2021, 2, 402-425.	1.1	6

#	ARTICLE	IF	CITATIONS
223	Erst einmal durchatmen!. Hautnah, 2021, 20, 114-115.	0.0	0
229	Commentary: Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 747109.	1.2	0
231	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
235	Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021. <i>Vaccine</i> , 2021, 39, 5456-5460.	1.7	37
236	Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 32-39.	1.2	18
237	India's COVID-19 vaccination drive: key challenges and resolutions. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1483-1484.	4.6	53
238	Stringent Nonpharmaceutical Interventions Are Crucial for Curbing COVID-19 Transmission in the Course of Vaccination: A Case Study of South and Southeast Asian Countries. <i>Healthcare (Switzerland)</i> , 2021, 9, 1292.	1.0	10
240	Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	46
241	Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	25
242	Temporal Analysis of SARS-CoV-2 Variants during the COVID-19 Pandemic in Nepal. <i>Covid</i> , 2021, 1, 423-434.	0.7	9
243	Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 1042.	2.1	64
244	Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons—Maryland, January â€“ May 2021. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	10
247	Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4128-4130.	1.4	1
251	New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status â€” New York, May 3â€“July 25, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1306-1311.	9.0	93
254	Recent advances and developments in COVIDâ€™19 in the context of allergic diseases. <i>Clinical and Translational Allergy</i> , 2021, 11, e12065.	1.4	7
256	Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. <i>Biochemical and Biophysical Research Communications</i> , 2021, 574, 14-19.	1.0	70
257	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
258	Exosome-mediated mRNA delivery inÂˆvivo is safe and can be used to induce SARS-CoV-2 immunity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101266.	1.6	64

#	ARTICLE	IF	CITATIONS
259	SARS-CoV-2 Delta variant infects ACE2 ^{low} primary human bronchial epithelial cells more efficiently than other variants. <i>Journal of Medical Virology</i> , 2022, 94, 821-822.	2.5	4
260	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	1.3	28
261	Using Lung Base Covid-19 Findings To Predict Future Disease Trends and New Variant Outbreaks: Study Of First New York City (NYC) Outbreak.. <i>Academic Radiology</i> , 2021, 28, 1645-1653.	1.3	1
262	The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil. <i>Frontiers in Public Health</i> , 2021, 9, 745310.	1.3	8
263	Booster Covid Vaccination- Luxury or Need?. <i>Annals of Medicine and Surgery</i> , 2021, 70, 102878.	0.5	3
264	Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects. <i>PLoS ONE</i> , 2021, 16, e0258236.	1.1	7
265	Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 338, 813-836.	4.8	30
266	COVID flood, can vaccines withstand?. <i>Medicine Updates</i> , 2021, 7, 51-62.	0.0	1
267	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
268	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. <i>EClinicalMedicine</i> , 2021, 41, 101143.	3.2	78
269	Weakening personal protective behavior by Chinese university students after COVID-19 vaccination. <i>Building and Environment</i> , 2021, 206, 108367.	3.0	24
270	Droplet digital RT-PCR to detect SARS-CoV-2 signature mutations of variants of concern in wastewater. <i>Science of the Total Environment</i> , 2021, 799, 149456.	3.9	92
271	COVID-19 challenges: From SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms. <i>Biochemical Engineering Journal</i> , 2021, 176, 108200.	1.8	17
272	A pH-engineering regenerative DNA tetrahedron ECL biosensor for the assay of SARS-CoV-2 RdRp gene based on CRISPR/Cas12a trans-activity. <i>Chemical Engineering Journal</i> , 2022, 429, 132472.	6.6	49
273	The Clinical Impact and Cost Effectiveness of Intervention Policies Against the SARS-CoV-2 Pandemic: A Mathematical Modelling Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
274	Vaccine Effectiveness Against Infection and Death Due to SARS-CoV-2, Following One and Two Doses of the BNT162b2 and ChAdOx-1 in Residents of Long-Term Care Facilities in England, Using a Time-Varying Proportional Hazards Model. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
275	Community Transmission and Viral Load Kinetics of SARS-CoV-2 Delta (B.1.617.2) Variant in Vaccinated and Unvaccinated Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
276	Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	22

#	ARTICLE	IF	CITATIONS
277	Vaccination against COVID-19 in pregnancy is safe and effective (literature review). Russian Journal of Human Reproduction, 2021, 27, 13.	0.1	0
278	Guangdong's Study of the Effectiveness of China's Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant. China CDC Weekly, 2021, 3, 728-730.	1.0	7
279	Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India. SSRN Electronic Journal, 0, , .	0.4	9
280	Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 43-54.	0.6	7
284	Correlation of Influenza Vaccination and the COVID-19 Severity. SSRN Electronic Journal, 0, , .	0.4	13
285	Stay at Home to Stay Safe: Effectiveness of Stay-at-Home Orders in Containing the COVID-19 Pandemic. SSRN Electronic Journal, 0, , .	0.4	5
286	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
287	SARS-CoV-2 Variants of Concern. Yonsei Medical Journal, 2021, 62, 961.	0.9	183
288	Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects?. Drug Discoveries and Therapeutics, 2021, 15, 278-280.	0.6	10
289	Are the COVID-19's vaccines efficient on the most dangerous variant of SARS-CoV-2?. Clinical and Experimental Vaccine Research, 2021, 10, 301.	1.1	0
290	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110501.	1.0	26
292	Effectiveness of COVID-19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 2021, 22, 1407.	0.8	23
294	The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant. Molecular Therapy, 2021, 29, 2890-2892.	3.7	19
295	Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members. JAMA Internal Medicine, 2021, 181, 1589.	2.6	15
296	Small Steps Towards Better Tracheostomy Care During the Evolving COVID-19 Pandemic. Journal of Intensive Care Medicine, 2021, 36, 088506662110490.	1.3	1
297	Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry, 2022, 21, 124-132.	4.8	105
298	COVID-19 interventions in children: a balancing act. Archives of Disease in Childhood, 2022, 107, e12-e12.	1.0	0
299	The challenges of COVID-19 Delta variant: Prevention and vaccine development. MedComm, 2021, 2, 846-854.	3.1	37

#	ARTICLE	IF	CITATIONS
300	Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity. Covid, 2021, 1, 472-488.	0.7	6
301	Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. CKJ: Clinical Kidney Journal, 2022, 15, 226-234.	1.4	30
302	SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker. Journal of Infection, 2022, 84, 418-467.	1.7	2
304	Cellular senescence as a source of SARS-CoV-2 quasispecies. FEBS Journal, 2023, 290, 1384-1392.	2.2	12
305	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
306	Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. New England Journal of Medicine, 2021, 385, 2101-2103.	13.9	82
307	COVID-19 Risk Assessment for the Tokyo Olympic Games. Frontiers in Public Health, 2021, 9, 730611.	1.3	9
309	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 2021, 600, 523-529.	13.7	194
311	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	5.9	94
312	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
314	Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. British Journal of Haematology, 2021, 196, e21.	1.2	11
315	Identification of antiviral phytochemicals as a potential SARS-CoV-2 main protease (Mpro) inhibitor using docking and molecular dynamics simulations. Scientific Reports, 2021, 11, 20295.	1.6	24
316	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus, 2021, 11, 20210008.	1.5	24
317	Analysis of the Delta Variant B.1.617.2 COVID-19. Clinics and Practice, 2021, 11, 778-784.	0.6	198
319	Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. JAMA Network Open, 2021, 4, e2128391.	2.8	44
320	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. Journal of Clinical Investigation, 2021, 131, .	3.9	49
321	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurology and Therapy, 2021, 10, 627-649.	1.4	9
324	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. Lancet Respiratory Medicine, 2021, 9, 1450-1466.	5.2	110

#	ARTICLE	IF	CITATIONS
325	Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. <i>EMBO Molecular Medicine</i> , 2021, 13, e14544.	3.3	17
326	Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients. <i>Viruses</i> , 2021, 13, 2011.	1.5	9
327	Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. <i>Science</i> , 2021, 374, 995-999.	6.0	230
328	Survival Analysis of Symptomatic COVID-19 in Phuentsholing Municipality, Bhutan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10929.	1.2	5
330	Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1086.	1.1	9
332	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
333	High association of COVID-19 severity with poor gut health score in Lebanese patients. <i>PLoS ONE</i> , 2021, 16, e0258913.	1.1	6
335	Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 217-218.	0.5	3
337	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. <i>Immunity and Ageing</i> , 2021, 18, 38.	1.8	20
340	A pragmatic approach to COVID-19 vaccine passport. <i>BMJ Global Health</i> , 2021, 6, e006956.	2.0	18
341	Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients. <i>Obstetrics and Gynecology</i> , 2022, 139, 107-109.	1.2	66
342	Indirect-Acting Pan-Antivirals vs. Respiratory Viruses: A Fresh Perspective on Computational Multi-Target Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 2687-2693.	1.0	5
343	Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. <i>New England Journal of Medicine</i> , 2021, 385, 2300-2301.	13.9	31
345	COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress. <i>Infectious Diseases of Poverty</i> , 2021, 10, 124.	1.5	17
347	Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage. <i>Frontiers in Physiology</i> , 2021, 12, 760638.	1.3	13
348	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement. <i>Vaccines</i> , 2021, 9, 1211.	2.1	5
349	Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2021, 41, 837-850.	1.2	6
350	Maximizing Completion of the Two-Dose COVID-19 Vaccine Series with Aid from Infographics. <i>Vaccines</i> , 2021, 9, 1229.	2.1	6

#	ARTICLE	IF	CITATIONS
352	One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. <i>Emerging Microbes and Infections</i> , 2021, 10, 2016-2029.	3.0	12
355	No one is safe until we are all safe. <i>Science Translational Medicine</i> , 2021, 13, eabl9900.	5.8	5
356	Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753249.	1.8	6
359	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. <i>Lancet, The</i> , 2021, 398, 1407-1416.	6.3	978
362	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
364	Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. <i>Cmaj</i> , 2021, 193, E1619-E1625.	0.9	220
369	Molecular modeling of the interaction of ligands with ACE2â€“SARS-CoV-2 spike protein complex. In <i>Silico Pharmacology</i> , 2021, 9, 55.	1.8	12
370	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	15.2	450
371	Genomic reconstruction of the SARS-CoV-2 epidemic in England. <i>Nature</i> , 2021, 600, 506-511.	13.7	80
372	Clinical Presentation of a COVID-19 Delta Variant Patient: Case Report and Literature Review. <i>Cureus</i> , 2021, 13, e18603.	0.2	5
374	Early COVID-19 Vaccination of Romanian Medical and Social Personnel. <i>Vaccines</i> , 2021, 9, 1127.	2.1	18
375	Uncertainty around the Long-Term Implications of COVID-19. <i>Pathogens</i> , 2021, 10, 1267.	1.2	16
377	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. <i>EBioMedicine</i> , 2021, 73, 103626.	2.7	43
378	Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2919-2922.	2.0	62
379	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
380	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112276.	2.5	9
381	Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in SÃ£o Paulo. <i>Nature Communications</i> , 2021, 12, 6220.	5.8	62
382	Lessons from Israel's COVID-19 Green Pass program. <i>Israel Journal of Health Policy Research</i> , 2021, 10, 61.	1.4	12

#	ARTICLE	IF	CITATIONS
383	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
384	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
385	Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study. <i>Lancet</i> , The, 2021, 398, 1825-1835.	6.3	119
386	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. <i>Science</i> , 2021, 374, 1353-1360.	6.0	246
387	Factors associated with COVID-19 Vaccine Hesitancy in Thai Seniors. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2389-2403.	0.8	40
388	Norovirus outbreak amid COVID-19 in the United Kingdom; priorities for achieving control. <i>Journal of Medical Virology</i> , 2022, 94, 1232-1235.	2.5	9
389	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 183-195.	4.6	585
391	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. <i>Water Research</i> , 2021, 207, 117808.	5.3	39
392	Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults. <i>Frontiers in Medicine</i> , 2021, 8, 756275.	1.2	11
393	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
394	Should COVID-19 vaccination be mandatory?. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 269-270.	1.7	8
395	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. <i>Lancet</i> , The, 2021, 398, 2093-2100.	6.3	748
396	Hospital Outbreak of the SARS-CoV-2 Delta Variant in Partially and Fully Vaccinated Patients and Healthcare Workers in Toronto, Canada. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-10.	1.0	9
397	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	2.2	46
399	What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 152-153.	4.6	46
400	Planning for the emergence of vaccine-resistant SARS-CoV-2: addressing revaccination delivery bottlenecks. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 014107682110526.	1.1	2
401	Waning Immunity after the BNT162b2 Vaccine in Israel. <i>New England Journal of Medicine</i> , 2021, 385, e85.	13.9	860
402	Comprehensive analyses of bioinformatics applications in the fight against COVID-19 pandemic. <i>Computational Biology and Chemistry</i> , 2021, 95, 107599.	1.1	21

#	ARTICLE	IF	CITATIONS
405	Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 513-524.	1.1	32
406	Disparities In County COVID-19 Vaccination Rates Linked To Disadvantage And Hesitancy. <i>Health Affairs</i> , 2021, 40, 1792-1796.	2.5	22
407	Impact of Delta Variant and Vaccination on SARS-CoV-2 Secondary Attack Rate Among Household Close Contacts. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 17, 100299.	1.3	49
408	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
409	Rapid differential diagnosis of the B.1.617.2 (delta) variant of SARS-CoV-2 using an automated Cas12a microfluidic system. <i>Chemical Communications</i> , 2021, 57, 12270-12272.	2.2	8
410	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of <i>Spike</i> Gene. <i>Immune Network</i> , 2021, 21, e32.	1.6	51
411	Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art. SSRN Electronic Journal, 0, , .	0.4	1
413	Decisive conditions for strategic vaccination against SARS-CoV-2. <i>Chaos</i> , 2021, 31, 101105.	1.0	4
414	Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1289-1297.	1.0	7
416	Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 2108-2110.	15.2	204
417	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. <i>Nature Communications</i> , 2021, 12, 6370.	5.8	3
419	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
420	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
421	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. <i>Science</i> , 2022, 375, 331-336.	6.0	202
422	Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1899-1905.	2.9	15
423	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
424	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
425	Nanotechnology Applications of Flavonoids for Viral Diseases. <i>Pharmaceutics</i> , 2021, 13, 1895.	2.0	24

#	ARTICLE	IF	CITATIONS
426	Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	51
429	Health QR Code Application in the Novel Containment Strategy and Healthcare Plan for Pregnant Women and Children Under Quarantine During the Summer Outbreak of SARS-CoV-2 Delta Variant in Chengdu, China: An Observational Study. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4499-4510.	1.2	5
430	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
431	Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. <i>Vaccines</i> , 2021, 9, 1286.	2.1	117
432	BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. <i>Science Immunology</i> , 2021, 6, eabl5344.	5.6	166
435	Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan. <i>Journal of Global Health</i> , 2021, 11, 05025.	1.2	12
437	Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 759108.	1.3	25
439	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. <i>Nature Communications</i> , 2021, 12, 6379.	5.8	214
440	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
441	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. <i>Antiviral Research</i> , 2021, 196, 105206.	1.9	1
442	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	6.0	111
444	Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. <i>New England Journal of Medicine</i> , 2021, 385, 2485-2487.	13.9	49
445	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.2	6
446	Overcoming Vaccine Hesitancy, Skepticism, and Hostility in Missouri. <i>Missouri Medicine</i> , 2021, 118, 396-400.	0.3	0
447	High-Throughput Adaptable SARS-CoV-2 Screening for Rapid Identification of Dominant and Emerging Regional Variants. <i>American Journal of Clinical Pathology</i> , 2022, 157, 927-935.	0.4	2
448	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 225, 327-331.	1.9	12
449	Treatment and therapeutic agents. , 2022, , 121-176.		0
450	Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. <i>Emerging Infectious Diseases</i> , 2022, 28, 36-44.	2.0	19

#	ARTICLE	IF	CITATIONS
451	Post-vaccination SARS-CoV-2 infection among healthcare workers in tertiary care hospitals in Saudi Arabia: A case series. <i>Journal of Infection and Public Health</i> , 2022, 15, 10-12.	1.9	8
452	Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case. <i>Preventive Medicine</i> , 2022, 154, 106890.	1.6	33
453	Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System. <i>Frontiers in Immunology</i> , 2021, 12, 689065.	2.2	6
454	Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 132.	1.5	244
455	Relationship of Problematic Smartphone Use, Sleep Quality, and Daytime Fatigue Among Quarantined Medical Students During the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 755059.	1.3	15
456	COVID-19 Vaccine Hesitancy in the United States: A Systematic Review. <i>Frontiers in Public Health</i> , 2021, 9, 770985.	1.3	172
458	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , 2021, 21, 2084.	1.2	30
460	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 473-482.	4.6	76
461	Sleep Quality and the Depression-Anxiety-Stress State of Frontline Nurses Who Perform Nucleic Acid Sample Collection During COVID-19: A Cross-Sectional Study. <i>Psychology Research and Behavior Management</i> , 2021, Volume 14, 1889-1900.	1.3	13
462	Hotspot Mutations in SARS-CoV-2. <i>Frontiers in Genetics</i> , 2021, 12, 753440.	1.1	14
463	Radiology Imaging Volume Changes During Discrete COVID-19 Pandemic Waves: Implications for the Delta Variant of Coronavirus and Future Pandemics. <i>Journal of the American College of Radiology</i> , 2021, , .	0.9	8
464	New Zealand's covid-19 policy switch will harm vulnerable people. <i>BMJ</i> , The, 2021, 375, n2738.	3.0	0
465	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 226-233.	2.0	46
466	Current COVID-19 vaccine epidemiology and dentistry. <i>Dental Update</i> , 2021, 48, 881-886.	0.1	0
467	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
468	Brought to Light: How Ultraviolet Disinfection Can Prevent the Nosocomial Transmission of COVID-19 and Other Infectious Diseases. <i>Applied Microbiology</i> , 2021, 1, 537-556.	0.7	11
471	Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100133.	1.5	11
472	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 2021, 10, .	2.8	63

#	ARTICLE	IF	CITATIONS
473	Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 349-356.	4.6	68
474	Current Review of Delta Variant of SARS-CoV-2. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 23-29.	0.1	5
477	Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital. <i>Cureus</i> , 2021, 13, e19487.	0.2	2
478	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
479	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. <i>Molecular Biomedicine</i> , 2021, 2, 38.	1.7	19
480	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. <i>Journal of Infectious Diseases</i> , 2022, 225, 598-602.	1.9	40
481	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
482	PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio. <i>Vaccines</i> , 2021, 9, 1381.	2.1	26
485	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 612.e1-612.e7.	2.8	231
486	Profiling vaccine believers and skeptics in nurses: A latent profile analysis. <i>International Journal of Nursing Studies</i> , 2022, 126, 104142.	2.5	19
487	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 214-227.	0.5	26
490	Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 425-426.	2.1	1
491	The glycosylation in SARS-CoV-2 and its receptor ACE2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 396.	7.1	111
492	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, e92.	13.9	53
493	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course. <i>Viruses</i> , 2021, 13, 2246.	1.5	6
494	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22
495	Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens. <i>Vaccines</i> , 2021, 9, 1412.	2.1	3
496	SARS-CoV-2 Targets and COVID-19 Vaccines. <i>Covid</i> , 2021, 1, 608-621.	0.7	4

#	ARTICLE	IF	CITATIONS
497	Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy. <i>Vaccines</i> , 2021, 9, 1354.	2.1	15
498	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
499	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
500	COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations. <i>Asia-Pacific Journal of Ophthalmology</i> , 2021, 10, 521-529.	1.3	23
501	Critical timing and extent of public health interventions to control outbreaks dominated by SARS-CoV-2 variants in Australia: a mathematical modelling study. <i>International Journal of Infectious Diseases</i> , 2022, 115, 154-165.	1.5	11
503	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1885-1897.	3.6	12
504	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
506	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
508	mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology. <i>Microbial Biotechnology</i> , 2022, 15, 135-148.	2.0	9
509	Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants. <i>ACS Omega</i> , 2021, 6, 31305-31320.	1.6	8
510	The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants. <i>Scientific Reports</i> , 2021, 11, 22970.	1.6	20
511	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
515	Functionalized Nanoparticles in Prevention and Targeted Therapy of Viral Diseases With Neurotropism Properties, Special Insight on COVID-19. <i>Frontiers in Microbiology</i> , 2021, 12, 767104.	1.5	6
516	Importância do acompanhamento e das intervenções relacionadas ao novo Corona Vírus (Sars-Cov-2), desde sua descoberta até os dias atuais – uma revisão da literatura. <i>Research, Society and Development</i> , 2021, 10, e579101422635.	0.0	0
517	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. <i>MBio</i> , 2021, 12, e0297521.	1.8	24
518	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
519	COVID-19 reinfection: the role of natural immunity, vaccines, and variants. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 733-739.	0.4	22
520	A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology. <i>Microbiology Spectrum</i> , 2021, 9, e0126721.	1.2	19

#	ARTICLE	IF	CITATIONS
521	Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. <i>Molecules</i> , 2021, 26, 6900.	1.7	53
522	A critical examination of policy objectives and instruments for a sustainable and inclusive post-pandemic recovery. <i>Fulbright Review of Economics and Policy</i> , 2021, 1, 140-157.	0.4	2
524	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
526	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
528	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 732403.	1.6	13
529	COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. <i>Healthcare (Switzerland)</i> , 2021, 9, 1566.	1.0	57
530	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100278.	3.0	109
533	COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly. <i>Vaccines</i> , 2021, 9, 1299.	2.1	58
534	Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January~September 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	20
535	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 2173-2184.	6.3	261
537	COVID-19 vaccines in the age of the delta variant. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 429-430.	4.6	6
538	The Pandemic Experience in Southeast Asia: Interface Between SARS-CoV-2, Malaria, and Dengue. <i>Frontiers in Tropical Diseases</i> , 2021, 2, .	0.5	7
539	Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases. <i>Infection</i> , 2021, , 1.	2.3	1
540	Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19. <i>Lancet</i> , The, 2021, 398, 2134-2135.	6.3	3
541	Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. <i>Vaccines</i> , 2021, 9, 1375.	2.1	37
543	Modeling the effect of the vaccination campaign on the COVID-19 pandemic. <i>Chaos, Solitons and Fractals</i> , 2022, 154, 111621.	2.5	29
545	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
546	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	1.8	6

#	ARTICLE	IF	CITATIONS
548	Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021. <i>Viruses</i> , 2021, 13, 2310.	1.5	9
551	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 320-331.	1.9	90
552	A Comparison of COVID-19 Stigma and AIDS Stigma During the COVID-19 Pandemic: A Cross-Sectional Study in China. <i>Frontiers in Psychiatry</i> , 2021, 12, 782501.	1.3	8
553	SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, Liberia, 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 3185-3188.	2.0	6
554	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.2	11
555	Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114030.	2.6	19
557	Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 663-680.	2.0	0
558	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
559	Emerging variants of concern in Saudi Arabian SARS-CoV-2 isolates. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2021, 42, 1366-1368.	0.5	0
560	At-home testing to mitigate community transmission of SARS-CoV-2: protocol for a public health intervention with a nested prospective cohort study. <i>BMC Public Health</i> , 2021, 21, 2209.	1.2	17
561	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
562	Heterologous Vaccination for Preparing COVID-19 Pandemic. <i>Korean Journal of Medicine</i> , 2021, 96, 450-454.	0.1	0
563	Acceptance of COVID-19 Vaccination among Healthcare and Non-Healthcare Workers of Hospitals and Outpatient Clinics in the Northern Region of Slovakia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12695.	1.2	14
564	Analysis of BNT162b2 and CVnCoV elicited sera and of convalescent sera toward SARS-CoV-2 viruses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, , .	2.7	9
565	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
566	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
567	Current and future nanoparticle vaccines for COVID-19. <i>EBioMedicine</i> , 2021, 74, 103699.	2.7	57
568	Effectiveness of COVID-19 vaccination in patients after allogeneic haematopoietic cell transplant: how much protection are we getting?. <i>British Journal of Haematology</i> , 2021, , .	1.2	0

#	ARTICLE	IF	CITATIONS
569	Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 801-812.	2.6	40
570	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
571	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	2.1	139
573	Overview of the first year of the SARS-CoV-2 pandemic in Serbia and the Pirot County. <i>Pirotski Zbornik</i> , 2021, , 1-23.	0.3	1
574	Effectiveness of message framing in changing COVID-19 vaccination intentions: Moderating role of travel desire. <i>Tourism Management</i> , 2022, 90, 104468.	5.8	52
575	A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
576	mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant. <i>SSRN Electronic Journal</i> , 0, , .	0.4	34
577	When Is It Valuable for COVID-19 Booster Dose?: A Transmission Dynamics Model-Based Effectiveness and Cost-Effectiveness Analysis of Two Booster Dose Vaccination Priority Strategies in Mainland China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
578	Vaccination against COVID-19 in pregnancy is safe and effective (literature review). <i>Russian Journal of Human Reproduction</i> , 2021, 27, 13.	0.1	0
579	Predictors of Uncertainty and Unwillingness to Receive the COVID-19 Booster Vaccine in a Sample of 22,139 Fully Vaccinated Adults in the UK. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
580	Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
581	Probability of Resurgence and Scale of Transmission of COVID-19 in China Depend on Passive Case Detection Capacity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
582	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
583	SIRVVD model-based verification of the effect of first and second doses of COVID-19/SARS-CoV-2 vaccination in Japan. <i>Mathematical Biosciences and Engineering</i> , 2021, 19, 1026-1040.	1.0	8
584	COVID-19 Vaccine Efficacy and the Evidence on Boosters. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
585	Effectiveness of BBV152/Covaxin and AZD1222/Covishield Vaccines Against Severe COVID-19 and B.1.617.2/Delta Variant in India, 2021: A Multi-Centric Hospital-Based Case-Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
586	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
587	Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3

#	ARTICLE	IF	CITATIONS
588	The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series. SSRN Electronic Journal, 0, , .	0.4	1
589	Risk of SARS-CoV-2 Reinfections in Children: Prospective National Surveillance, January 2020 to July 2021, England. SSRN Electronic Journal, 0, , .	0.4	0
590	Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control Trial. SSRN Electronic Journal, 0, , .	0.4	1
591	Efficacy and effectiveness of COVID-19 vaccines: Progress and prospect. , 2021, 1, 17.		2
592	Challenges in management of ST elevation myocardial infarction during COVID-19 pandemic. Cardiology Plus, 2021, 6, 218.	0.2	2
593	Alpha, delta and now Omicron: When will the COVID-19 pandemic end?. Current Medical Issues, 2021, 19, 221.	0.1	13
594	COVID-19 in pregnancy by race and ethnicity: Implications for development of a vaccination strategy. Women's Health, 2021, 17, 174550652110633.	0.7	5
595	Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model. Vacunas, 2022, , .	1.1	0
596	Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients. Frontiers in Medicine, 2021, 8, 792135.	1.2	42
597	SARS-CoV2 vaccine boosters for India. Indian Journal of Medical Microbiology, 2022, 40, 1-1.	0.3	0
599	Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers. American Journal of Tropical Medicine and Hygiene, 2022, 106, 556-561.	0.6	12
600	Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries. EClinicalMedicine, 2022, 43, 101253.	3.2	10
601	Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study ;In the U.S. Veterans Affairs Healthcare System. SSRN Electronic Journal, 0, , .	0.4	0
603	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology, 2022, 7, 277-288.	5.9	37
604	Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines, 2022, 10, 86.	2.1	62
606	A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. International Journal of Biological Sciences, 2022, 18, 889-900.	2.6	40
607	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection, 2022, 84, 675-683.	1.7	87
608	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. Clinical Ophthalmology, 2022, Volume 16, 1-13.	0.9	16

#	ARTICLE	IF	CITATIONS
609	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 665.	1.3	8
610	Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. <i>Current Opinion in Virology</i> , 2022, 52, 89-101.	2.6	2
611	Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases. <i>Biochemical Society Transactions</i> , 2022, 50, 151-165.	1.6	8
612	Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. <i>Journal of Autoimmunity</i> , 2022, 127, 102792.	3.0	96
613	Multilevel determinants of COVID-19 vaccination hesitancy in the United States: A rapid systematic review. <i>Preventive Medicine Reports</i> , 2022, 25, 101673.	0.8	71
614	Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. <i>Preventive Medicine</i> , 2022, 155, 106947.	1.6	27
615	No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. <i>International Journal of Infectious Diseases</i> , 2022, 115, 178-184.	1.5	31
616	Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel. <i>Emerging Infectious Diseases</i> , 2022, 28, 338-346.	2.0	25
617	Comparative mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional implications using computational modelling and simulation approaches. <i>Computers in Biology and Medicine</i> , 2022, 141, 105170.	3.9	15
618	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100154.	1.5	55
619	Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants. <i>Emerging Infectious Diseases</i> , 2022, 28, 331-337.	2.0	32
620	DeepMGT-DTI: Transformer network incorporating multilayer graph information for Drug-Target interaction prediction. <i>Computers in Biology and Medicine</i> , 2022, 142, 105214.	3.9	33
621	SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. <i>Immune Network</i> , 2021, 21, e38.	1.6	42
622	County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
623	Delta variant of SARS-CoV-2: characteristics and implications for public health in Colombia. <i>Revista Facultad De Medicina</i> , 2021, 70, e97460.	0.0	1
624	Estimating the effect of timetabling decisions on the spread of SARS-CoV-2 in medium-to-large engineering schools in Canada: an agent-based modelling study. <i>CMAJ Open</i> , 2021, 9, E1252-E1259.	1.1	1
627	Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. <i>Clinical and Translational Medicine</i> , 2021, 11, e644.	1.7	7
628	Epidemiological features of COVID-19 patients with prolonged incubation period and its implications for controlling the epidemics in China. <i>BMC Public Health</i> , 2021, 21, 2239.	1.2	2

#	ARTICLE	IF	CITATIONS
629	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
630	Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T _A cell responses. <i>Cell Reports Medicine</i> , 2022, 3, 100520.	3.3	29
631	Vaccination strategies between compulsion and incentives. The Italian Green Pass experience. <i>Expert Review of Vaccines</i> , 2022, 21, 423-425.	2.0	12
632	A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. <i>Frontiers in Microbiology</i> , 2021, 12, 803827.	1.5	3
633	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
634	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	3.7	24
635	Influence of Adult Attachment on COVID-19 Vaccination Intention: The Mediating Roles of Help-Seeking Style and Professional Help-Seeking Behavior. <i>Vaccines</i> , 2022, 10, 221.	2.1	1
636	Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations. <i>Chemical Papers</i> , 2022, 76, 2759-2776.	1.0	28
637	Immunological challenges of the "new" infections: corona viruses. , 2022, , 395-450.		2
638	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. <i>Med</i> , 2022, 3, 28-41.e8.	2.2	19
639	Coronavirus vaccination rates in cultural areas in Germany. <i>Epidemiology and Infection</i> , 2022, 150, 1-9.	1.0	1
640	Clinical characteristics of COVID-19 in solid organ transplant recipients following COVID-19 vaccination: A multicenter case series. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	16
641	A short plus long-amplicon based sequencing approach improves genomic coverage and variant detection in the SARS-CoV-2 genome. <i>PLoS ONE</i> , 2022, 17, e0261014.	1.1	11
642	SARS-CoV-2 Virology. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 251-265.	1.9	7
645	Adopting population-based interventions towards sustaining child health services in the midst of COVID-19 in sub-Saharan Africa: application of the socio-ecological model. <i>Pan African Medical Journal</i> , 2022, 41, 70.	0.3	1
648	Insights Into the Changing Landscape of Coronavirus Disease 2019. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 761521.	1.8	11
649	Harnessing Artificial Intelligence to assess the impact of nonpharmaceutical interventions on the second wave of the Coronavirus Disease 2019 pandemic across the world. <i>Scientific Reports</i> , 2022, 12, 944.	1.6	7
650	Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women. <i>Vaccines</i> , 2022, 10, 101.	2.1	23

#	ARTICLE	IF	CITATIONS
651	Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. <i>Vaccine</i> , 2022, 40, 701-705.	1.7	40
652	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 720-728.	0.5	39
653	Innovative vaccine approaches—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
654	Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2. <i>Royal Society Open Science</i> , 2022, 9, 211021.	1.1	8
655	Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. <i>AIDS Research and Therapy</i> , 2022, 19, 3.	0.7	65
656	Analyses of Confirmed COVID-19 Cases Among Korean Military Personnel After Mass Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, e23.	1.1	4
657	Airborne Isolation Cardiac Arrest: A Simulation Program for Interdisciplinary Code Blue Team Training. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2022, 18, 11213.	0.5	0
661	Successful treatment of an 82-year-old COVID-19 delta variant-infected patient with haemorrhagic stroke and active prostate cancer brain metastasis. <i>Clinical and Translational Discovery</i> , 2022, 2, e20.	0.2	0
662	A Retrospective Cross-Sectional Study of Severe Breakthrough SARS-CoV-2 Infection in the General Population Requiring Hospitalization Within a Single Health System. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 45-52.	0.6	1
663	Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. <i>Journal of Health Economics</i> , 2022, 82, 102589.	1.3	23
664	Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, , 102527.	1.7	1
665	Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 807454.	2.2	13
666	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
667	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
668	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. <i>Lancet Respiratory Medicine</i> , 2022, 10, 355-366.	5.2	39
669	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
670	Contact tracing period and epidemiological characteristics of an outbreak of the SARS-CoV-2 Delta variant in Guangzhou. <i>International Journal of Infectious Diseases</i> , 2022, 117, 18-23.	1.5	8
672	Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants. <i>Journal of Microbiology</i> , 2022, 60, 347-354.	1.3	9

#	ARTICLE	IF	CITATIONS
673	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2022, 399, 461-472.	6.3	69
674	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
675	Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. <i>Vaccines</i> , 2022, 10, 154.	2.1	8
676	Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine. <i>Vaccines</i> , 2022, 10, 177.	2.1	3
678	OUP accepted manuscript. <i>International Health</i> , 2022, , .	0.8	0
679	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
680	SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. <i>JAMA Network Open</i> , 2022, 5, e2142210.	2.8	48
681	Risk of SARS-CoV-2 Reinfection and COVID-19 Hospitalisation in Individuals With Natural- and Hybrid Immunity: A Retrospective, Total Population Cohort Study in Sweden. <i>SSRN Electronic Journal</i> , 0, , .	0.4	13
682	Complex Contact Network of Patients at the Beginning of an Epidemic Outbreak: An Analysis Based on 1218 COVID-19 Cases in China. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 689.	1.2	9
683	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. <i>BMC Medicine</i> , 2022, 20, 29.	2.3	20
684	Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	4
685	Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico. <i>Viruses</i> , 2022, 14, 154.	1.5	7
686	SARS-CoV-2 Infection in Vaccinated Health Care Workers. <i>New England Journal of Medicine</i> , 2022, 386, 199-200.	13.9	2
687	Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 37-39.	1.0	7
688	Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 483-489.	1.4	5
689	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. <i>Cell Host and Microbe</i> , 2022, 30, 69-82.e10.	5.1	42
690	Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1058-1064.	0.9	2
691	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	1.5	1

#	ARTICLE	IF	CITATIONS
692	Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1716-1737.	0.7	22
693	The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. <i>Vaccines</i> , 2022, 10, 81.	2.1	26
694	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. <i>Vaccines</i> , 2022, 10, 82.	2.1	16
696	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. <i>Life</i> , 2022, 12, 194.	1.1	25
697	Modeling and optimal control of mutated COVID-19 (Delta strain) with imperfect vaccination. <i>Chaos, Solitons and Fractals</i> , 2022, 156, 111825.	2.5	41
698	The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion. <i>Viruses</i> , 2022, 14, 294.	1.5	85
699	From Alpha to Omicron SARS-CoV-2 variants: What their evolutionary signatures can tell us?. <i>Journal of Medical Virology</i> , 2022, 94, 1773-1776.	2.5	16
700	Will the COVID-19 pandemic end with the Delta and Omicron variants?. <i>Environmental Chemistry Letters</i> , 2022, 20, 2215-2225.	8.3	36
701	Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England. <i>Nature Medicine</i> , 0, , .	15.2	6
702	Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants. <i>Epidemiology and Infection</i> , 2022, 150, 1-22.	1.0	9
703	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <i>Cell</i> , 2022, 185, 457-466.e4.	13.5	881
705	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
706	The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1767-1772.	1.0	25
707	Role of Probiotics in the Management of COVID-19: A Computational Perspective. <i>Nutrients</i> , 2022, 14, 274.	1.7	40
708	Endogenous viral mutations, evolutionary selection, and containment policy design. <i>Journal of Economic Interaction and Coordination</i> , 2022, 17, 801-825.	0.4	4
709	Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria–Spikevax vaccination. <i>European Journal of Immunology</i> , 2022, 52, 356-359.	1.6	7
710	Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. <i>BMC Medicine</i> , 2022, 20, 37.	2.3	10
711	Challenges Faced in Large-Scale Nucleic Acid Testing during the Sudden Outbreak of the B.1.617.2 (Delta). <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1573.	1.2	6

#	ARTICLE	IF	CITATIONS
712	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
713	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
714	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
715	<scp>COVID</scp>â€19 infection and the broader impacts of the pandemic on healthcare workers. <i>Respirology</i> , 2022, 27, 411-426.	1.3	63
716	Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1073.	1.2	4
717	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. <i>ELife</i> , 2022, 11, .	2.8	19
718	Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant. <i>Cellular and Molecular Immunology</i> , 2022, 19, 445-446.	4.8	19
720	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. <i>Lancet, The</i> , 2022, 399, 25-35.	6.3	109
721	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
722	Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic. <i>Expert Review of Vaccines</i> , 2022, 21, 427-430.	2.0	30
723	Digital Microfluidic qPCR Cartridge for SARS-CoV-2 Detection. <i>Micromachines</i> , 2022, 13, 196.	1.4	16
724	Differing kinetics of antiâ€spike protein IgGs and neutralizing antibodies against SARSâ€CoV â€2 after Comirnaty (BNT162b2) immunization. <i>Journal of Applied Microbiology</i> , 2022, , .	1.4	4
725	Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence â€ China, 2021. <i>China CDC Weekly</i> , 2022, 4, 57-65.	1.0	36
726	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	2.2	19
727	Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. <i>Nature Medicine</i> , 2022, 28, 831-837.	15.2	284
729	Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. <i>New England Journal of Medicine</i> , 2022, 386, 744-756.	13.9	323
730	The Emergence of Omicron: Challenging Times Are Here Again!. <i>Indian Journal of Pediatrics</i> , 2022, 89, 490-496.	0.3	70
731	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120

#	ARTICLE	IF	CITATIONS
732	The Evolution of a Hospital-Based Covid-19 Vaccination Program for Inpatients. <i>NEJM Catalyst</i> , 2022, 3, .	0.4	4
733	Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
734	Testing strategies to contain COVID-19 in migrant worker dormitories. <i>Journal of Migration and Health</i> , 2022, 5, 100079.	1.6	2
735	Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination. <i>The Lancet Global Health</i> , 2022, 10, e33-e34.	2.9	19
736	Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 808932.	2.2	34
737	Intrauterine Fetal Demise in the Third Trimester of Pregnancy Associated With Mild Infection With the SARS-CoV-2 Delta Variant Without Protection From Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 225, 748-753.	1.9	18
738	Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. <i>Vaccines</i> , 2022, 10, 68.	2.1	22
741	Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, 3.	6.9	28
744	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. <i>Life</i> , 2022, 12, 57.	1.1	6
746	Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. <i>EMBO Molecular Medicine</i> , 2022, 14, e15227.	3.3	31
747	Sustainable supplier selection and order allocation for multinational enterprises considering supply disruption in COVID-19 era. <i>Australian Journal of Management</i> , 2023, 48, 284-322.	1.2	13
748	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 37.	0.9	2
749	Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective. <i>International Journal of Public Health</i> , 2021, 66, 1604312.	1.0	4
750	Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1293-1305.	1.6	28
751	SARS-CoV-2 spike protein inhibits growth of prostate cancer: a potential role of the COVID-19 vaccine killing two birds with one stone. <i>Medical Oncology</i> , 2022, 39, 32.	1.2	8
753	Infection Pattern, Treatment Protocols and Post-COVID-19 Complications—A Survey on 706 COVID-19 Recovered Participants. <i>Exploratory Research and Hypothesis in Medicine</i> , 2022, 000, 000-000.	0.1	0
754	mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 821538.	2.2	11
755	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	5.8	92

#	ARTICLE	IF	CITATIONS
756	Questionnaire Survey on COVID-19 Vaccination at Okayama University in Japan: Factors Promoting Vaccination Among Young Adults. <i>Journal of Disaster Research</i> , 2022, 17, 21-30.	0.4	1
757	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 649-656.	4.6	12
758	Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients. <i>Transplantation</i> , 2022, 106, 436-446.	0.5	76
759	Secondary transmission of SARS-CoV-2 during the first two waves in Japan: Demographic characteristics and overdispersion. <i>International Journal of Infectious Diseases</i> , 2022, 116, 365-373.	1.5	11
760	Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2022, 226, 485-496.	1.9	8
761	Cytopathic Effect Assay and Plaque Assay to Evaluate in vitro Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63. <i>Bio-protocol</i> , 2022, 12, e4314.	0.2	4
763	Knowledge about COVID-19 vaccine and vaccination in Vietnam: A population survey. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, , .	0.7	6
764	Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. <i>Vaccine</i> , 2022, 40, 691-694.	1.7	32
765	Impact of vaccination on the COVID-19 pandemic in U.S. states. <i>Scientific Reports</i> , 2022, 12, 1554.	1.6	54
766	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
769	A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials. <i>International Journal of Pharma and Bio Sciences</i> , 2022, 12, 55-71.	0.1	0
770	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
771	Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. <i>Science Immunology</i> , 2022, 7, eabn8014.	5.6	220
772	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 494-496.	13.9	570
773	An exploratory study on the propagation of SARS-CoV-2 variants: Omicron is the most predominant variant. <i>Journal of Medical Virology</i> , 2022, 94, 2414-2421.	2.5	16
774	Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution. <i>American Journal of Emergency Medicine</i> , 2022, 54, 97-101.	0.7	6
775	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). <i>Scientific Reports</i> , 2022, 12, 1727.	1.6	11
776	Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants. <i>Research</i> , 2022, 2022, 9781758.	2.8	15

#	ARTICLE	IF	CITATIONS
778	SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021. <i>American Journal of Emergency Medicine</i> , 2022, 54, 81-86.	0.7	3
780	SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance – Los Angeles County, California, November 7, 2021–January 8, 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 177-181.	9.0	88
782	Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. <i>Journal of Medical Virology</i> , 2022, 94, 2188-2200.	2.5	20
783	Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China. <i>Annals of Internal Medicine</i> , 2022, 175, 533-540.	2.0	52
784	Stay at home to stay safe: Effectiveness of stay-at-home orders in containing the COVID-19 pandemic. <i>Production and Operations Management</i> , 2022, 31, 2289-2305.	2.1	8
785	Breakthrough COVID-19 Infections: What Are They and What Do They Look Like?. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, .	0.9	1
786	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
787	Conditionality of COVID-19 vaccine acceptance in European countries. <i>Vaccine</i> , 2022, 40, 1191-1197.	1.7	17
788	Susceptibility of sheep to experimental co-infection with the ancestral lineage of SARS-CoV-2 and its alpha variant. <i>Emerging Microbes and Infections</i> , 2022, 11, 662-675.	3.0	21
789	Vaccination status among patients with the need for emergency hospitalizations related to COVID-19. <i>American Journal of Emergency Medicine</i> , 2022, 54, 102-106.	0.7	6
790	Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. <i>Vaccine</i> , 2022, 40, 1829-1836.	1.7	7
791	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
792	Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 177-185.	0.6	23
793	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. <i>Infection</i> , 2022, , 1.	2.3	15
794	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, .	2.3	12
795	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
796	Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. <i>American Journal of Emergency Medicine</i> , 2022, 54, 46-57.	0.7	146
797	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 21, 100389.	1.3	16

#	ARTICLE	IF	CITATIONS
798	First nosocomial cluster of COVID-19 due to the Delta variant in a major acute care hospital in Singapore: investigations and outbreak response. <i>Journal of Hospital Infection</i> , 2022, 122, 27-34.	1.4	16
799	Changing air pollution and CO2 emissions during the COVID-19 pandemic: Lesson learned and future equity concerns of post-COVID recovery. <i>Environmental Science and Policy</i> , 2022, 130, 1-8.	2.4	12
800	County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100191.	1.5	13
801	The Influence of New SARS-CoV-2 Variant Omicron (B.1.1.529) on Vaccine Efficacy, its Correlation to Delta Variants: A Computational Approach. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
802	Aerosolized Nanobodies Prevent Infections of SARS-CoV-2 in PrEP and PEP Settings in Mice and are Effective to Variants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
803	Pandemic Analysis V: The Science and Economics of a Vaccine for Ending the Pandemic. , 2022, , 199-232.		0
804	Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 882-890.	1.9	10
805	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). <i>Clinical Infectious Diseases</i> , 2022, 75, e630-e644.	2.9	65
806	Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study. <i>Vaccine</i> , 2022, 40, 3294-3297.	1.7	19
808	A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. <i>EMBO Molecular Medicine</i> , 2022, 14, e15298.	3.3	23
809	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
810	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
811	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	30
813	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. <i>Lancet, The</i> , 2022, 399, 814-823.	6.3	196
814	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. <i>Molecular Diversity</i> , 2022, 26, 3309-3324.	2.1	17
815	Testing fractional doses of COVID-19 vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	20
816	Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England. <i>Journal of Infection</i> , 2022, 84, 692-700.	1.7	13
817	Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population. <i>Vaccines</i> , 2022, 10, 260.	2.1	14

#	ARTICLE	IF	CITATIONS
818	Data-driven testing program improves detection of COVID-19 cases and reduces community transmission. <i>Npj Digital Medicine</i> , 2022, 5, 17.	5.7	1
819	Impact of prior vaccination with Covishield™ and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study. <i>Vaccine</i> , 2022, 40, 2107-2107.	1.7	17
820	A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 962-964.	0.8	1
822	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 585-592.	3.0	50
823	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. <i>Journal of the International AIDS Society</i> , 2022, 25, e25882.	1.2	2
824	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
826	A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	94
827	Fractional stochastic modelling of COVID-19 under wide spread of vaccinations: Egyptian case study. <i>AEJ - Alexandria Engineering Journal</i> , 2022, 61, 8595-8609.	3.4	17
828	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	1.4	12
829	Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. <i>Molecular Therapy</i> , 2022, 30, 1979-1993.	3.7	15
830	Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. <i>BMJ</i> , The, 2022, 376, e069052.	3.0	67
831	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194
832	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
834	SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021. <i>MBio</i> , 2022, 13, e0378821.	1.8	11
835	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. <i>BMC Medicine</i> , 2022, 20, 52.	2.3	7
836	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
837	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	5.6	12
841	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337

#	ARTICLE	IF	CITATIONS
842	Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review. BMC Infectious Diseases, 2022, 22, 140.	1.3	16
843	Myocarditis following mRNA Covid-19 vaccination: A pooled analysis. Vaccine, 2022, 40, 1768-1774.	1.7	19
844	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nature Communications, 2022, 13, 742.	5.8	71
845	Projecting the impact of Covid-19 variants and vaccination strategies in disease transmission using a multilayer network model in Costa Rica. Scientific Reports, 2022, 12, 2279.	1.6	8
846	Numerical evaluation of face masks for prevention of COVID-19 airborne transmission. Environmental Science and Pollution Research, 2022, 29, 44939-44953.	2.7	10
847	Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera. Viruses, 2022, 14, 335.	1.5	12
848	Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. International Journal of Infectious Diseases, 2022, 116, 204-209.	1.5	31
849	COVID-19 vaccination and breakthrough infections in patients with cancer. Annals of Oncology, 2022, 33, 340-346.	0.6	76
850	Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK. Lancet Regional Health - Europe, The, 2022, 14, 100317.	3.0	70
852	Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection. JAMA - Journal of the American Medical Association, 2022, 327, 179.	3.8	89
853	The variants of SARS-CoV-2 and the challenges of vaccines. Journal of Medical Virology, 2022, 94, 1366-1372.	2.5	29
854	Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. Infection, 2022, 50, 671-679.	2.3	20
855	An analysis of the COVID-19 vaccination campaigns in France, Israel, Italy and Spain and their impact on health and economic outcomes. Health Policy and Technology, 2022, 11, 100594.	1.3	35
856	Diagnostics for COVID-19: moving from pandemic response to control. Lancet, The, 2022, 399, 757-768.	6.3	230
857	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infectious Diseases, The, 2022, 22, 483-495.	4.6	232
858	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217.	5.8	80
859	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	10.6	217
860	Covid-19 Rates by Time since Vaccination during Delta Variant Predominance. , 2022, 1, .		7

#	ARTICLE	IF	CITATIONS
861	Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e849-e856.	2.9	23
862	Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure. <i>Clinical Infectious Diseases</i> , 2022, 75, e276-e288.	2.9	21
863	Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. <i>Clinical Infectious Diseases</i> , 2022, 75, e715-e725.	2.9	130
864	Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e185-e190.	2.9	60
865	The Epidemiology of COVID-19 in Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 110-122.	0.6	36
866	SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 421-430.	0.6	10
884	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. <i>Microbial Biotechnology</i> , 2022, 15, 721-737.	2.0	41
885	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ, The</i> , 2021, 375, e068848.	3.0	180
886	A Case-Control Study for the Effectiveness of Oral Zinc in the Prevention and Mitigation of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 756707.	1.2	12
887	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13345.	1.2	11
888	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. <i>Vaccines</i> , 2021, 9, 1442.	2.1	18
889	Rapid impact assessments of COVID-19 control measures against the Delta variant and short-term projections of new confirmed cases in Vietnam. <i>Journal of Global Health</i> , 2021, 11, 03118.	1.2	18
890	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	6.5	175
891	The first confirmed SARS-CoV-2 delta variant in Serbia. <i>Medicinski Casopis</i> , 2021, 55, 104-107.	0.1	0
892	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
893	Safe at Last? Late Effects of a Mass Immunization Campaign on Households' Economic Insecurity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
894	Effectiveness of mRNA COVID-19 Vaccines in Japan during the Nationwide Pandemic of the Delta Variant. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 257, 1-6.	0.5	6
895	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	1.3	7

#	ARTICLE	IF	CITATIONS
896	Impaired Humoral Immunity Is Associated With Prolonged COVID-19 Despite Robust CD8 T-Cell Responses. SSRN Electronic Journal, 0, , .	0.4	0
897	Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic. Journal of Korean Medical Science, 2022, 37, e67.	1.1	3
898	Vaccine Effectiveness of Two and Three Doses of BNT162b2 and Coronavac Against COVID-19 in Hong Kong. SSRN Electronic Journal, 0, , .	0.4	26
899	Improving vaccination coverage and offering vaccine to all school-age children allowed uninterrupted in-person schooling in King County, WA: Modeling analysis. Mathematical Biosciences and Engineering, 2022, 19, 5699-5716.	1.0	2
900	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
901	Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan. Tohoku Journal of Experimental Medicine, 2022, , .	0.5	2
902	The Global dynamics of a SIR model considering competitions among multiple strains in patchy environments. Mathematical Biosciences and Engineering, 2022, 19, 4690-4702.	1.0	3
903	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
904	æ-°ăžă,3ăfăfŠă, ă,ăf«ă,1ă«ă-3/4ă™ă,«æ2»ç™,ăf»ă°é². Nihon Toseki Igakkai Zasshi, 2022, 55, 129-136.	0.2	1
905	Effectiveness of the emergency public activity restrictions on COVID-19 epidemiological parameter in East Java Province, Indonesia: An ecological study. Asian Journal of Social Health and Behavior, 2022, 5, 33.	2.0	19
906	Surveillance of COVID-19 vaccine effectiveness: a real-time caseâ€“control study in southern Sweden. Epidemiology and Infection, 2022, 150, 1-15.	1.0	3
907	Covishieldâ„¢ (ChAdOx1) vaccine effectiveness and epidemiological risk factors of COVID-19 infection among frontline workers during second wave of COVID-19 pandemic, New Delhi: A caseâ€“control study. Journal of Marine Medical Society, 2022, 24, 101.	0.0	0
909	Knowledge, Attitudes, and Perception towards COVID-19 Vaccination among the Adult Population: A Cross-Sectional Study in Turkey. Vaccines, 2022, 10, 278.	2.1	19
910	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. Pathogens, 2022, 11, 275.	1.2	9
911	High diversity in Delta variant across countries revealed by genomeâ€“wide analysis of SARSâ€“CoVâ€“2 beyond the Spike protein. Molecular Systems Biology, 2022, 18, e10673.	3.2	18
912	Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis. BMC Medicine, 2022, 20, 80.	2.3	10
913	Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907.	5.8	94
914	Antibody response to COVID-19 vaccination in patients with lymphoma. International Journal of Hematology, 2022, 115, 728-736.	0.7	13

#	ARTICLE	IF	CITATIONS
916	Vaccines alone will not prevent COVID-19 outbreaks among migrant workers—the example of meat processing plants. <i>Clinical Microbiology and Infection</i> , 2022, 28, 773-778.	2.8	13
917	Incidence of COVID-19 infection in hospital workers from March 1, 2020 to May 31, 2021 routinely tested, before and after vaccination with BNT162B2. <i>Scientific Reports</i> , 2022, 12, 2533.	1.6	9
918	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study. <i>Journal of Infection</i> , 2022, 84, 171-178.	1.7	25
919	Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 96-100.	0.2	18
920	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
921	Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. <i>BMJ Global Health</i> , 2022, 7, e007236.	2.0	13
923	Healthcare Disparities and Outcomes of Cancer Patients in a Community Setting from a COVID-19 Epicenter. <i>Current Oncology</i> , 2022, 29, 1150-1162.	0.9	1
924	Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease. <i>Vaccines</i> , 2022, 10, 298.	2.1	1
925	The Delta Variant Triggers the Third Wave of COVID-19 in Mexico. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, , 1-3.	0.7	1
926	Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 557-565.	5.2	44
927	Durability and expansion of neutralizing antibody breadth following Ad26.COVS.2S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
928	COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 812606.	2.2	15
929	Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 1479-1487.	0.9	18
930	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
931	Global impact of delta plus variant and vaccination. <i>Expert Review of Vaccines</i> , 2022, 21, 597-600.	2.0	41
932	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. <i>Pharmaceuticals</i> , 2022, 15, 258.	1.7	20
933	Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals. <i>Vaccines</i> , 2022, 10, 332.	2.1	10
934	Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. <i>Journal of Infectious Diseases</i> , 2022, 226, 808-811.	1.9	7

#	ARTICLE	IF	CITATIONS
935	How to organise travel restrictions in the new future: lessons from the COVID-19 response in Hong Kong and Singapore. <i>BMJ Global Health</i> , 2022, 7, e006975.	2.0	4
936	Successive Pandemic Waves with Different Virulent Strains and the Effects of Vaccination for SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 343.	2.1	4
937	A COVID-19 vaccination model for Aotearoa New Zealand. <i>Scientific Reports</i> , 2022, 12, 2720.	1.6	25
938	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
939	COVID-19 mortality prediction in the intensive care unit with deep learning based on longitudinal chest X-rays and clinical data. <i>European Radiology</i> , 2022, 32, 4446-4456.	2.3	19
940	Molecular and Serologic Investigation of the 2021 COVID-19 Case Surge Among Vaccine Recipients in Mongolia. <i>JAMA Network Open</i> , 2022, 5, e2148415.	2.8	4
943	A Safe Return to Campus in Times of COVID-19: A Survey Study among University Personnel to Inform Decision Makers. <i>Vaccines</i> , 2022, 10, 371.	2.1	1
944	COVID-19 Vaccines: An Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 72.	1.6	32
945	COVID-19 can be called a treatable disease only after we have antivirals. <i>Science Bulletin</i> , 2022, 67, 999-1002.	4.3	5
946	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 277.	2.1	15
947	Delta Variant with P681R Critical Mutation Revealed by Ultra-Large Atomic-Scale Ab Initio Simulation: Implications for the Fundamentals of Biomolecular Interactions. <i>Viruses</i> , 2022, 14, 465.	1.5	11
948	A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 324-325.	0.7	3
950	COVID-19: A systematic review and update on prevention, diagnosis, and treatment. <i>MedComm</i> , 2022, 3, e115.	3.1	30
951	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
952	Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 871-878.	2.8	31
953	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. <i>ELife</i> , 2022, 11, .	2.8	26
954	Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. <i>Vaccines</i> , 2022, 10, 323.	2.1	1
955	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. <i>Frontiers in Microbiology</i> , 2022, 13, 828806.	1.5	17

#	ARTICLE	IF	CITATIONS
956	Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 603-610.	4.6	154
957	Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 769-778.	0.9	15
958	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	15.2	147
959	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1073-1076.	2.6	44
960	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 285.	2.1	13
963	A potential silver lining of delaying the second dose. <i>Nature Immunology</i> , 2022, 23, 349-351.	7.0	8
965	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
966	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 566-572.	5.2	23
967	Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination. <i>Journal of Infection</i> , 2022, 84, e45-e47.	1.7	6
968	Low antispikes antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations. <i>Journal of Internal Medicine</i> , 2022, 292, 127-135.	2.7	15
969	A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 964-967.	3.0	12
970	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
971	Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1207-1220.	13.9	452
972	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
973	A Correlation Study of COVID-19 in Europe Considering Different Vaccines, Age Groups and Variants Including Delta and Omicron. <i>BioMed</i> , 2022, 2, 133-169.	0.6	1
974	Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. <i>Stem Cell Research and Therapy</i> , 2022, 13, 124.	2.4	17
975	COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data. <i>BMJ Open</i> , 2022, 12, e057741.	0.8	5
977	Rapid Antigen Assays for SARS-CoV-2. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 203-222.	0.7	9

#	ARTICLE	IF	CITATIONS
978	Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-28.	0.9	7
979	Why Controlling the Asymptomatic Infection Is Important: A Modelling Study with Stability and Sensitivity Analysis. <i>Fractal and Fractional</i> , 2022, 6, 197.	1.6	10
980	Detection of SARS-CoV-2 and the L452R spike mutation using reverse transcription loop-mediated isothermal amplification plus bioluminescent assay in real-time (RT-LAMP-BART). <i>PLoS ONE</i> , 2022, 17, e0265748.	1.1	8
981	The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series. <i>International Journal of Emergency Medicine</i> , 2022, 15, 9.	0.6	3
982	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	6.0	177
983	A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine. <i>Journal of Community Health</i> , 2022, 47, 598-603.	1.9	9
984	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). <i>Frontiers in Immunology</i> , 2022, 13, 865401.	2.2	8
985	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
987	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
988	The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 793-803.	3.0	14
989	Risk Stratification of SARS-CoV-2 Breakthrough Infections Based on an Outbreak at a Student Festive Event. <i>Vaccines</i> , 2022, 10, 432.	2.1	0
990	Factors Related to Non-compliance With Non-pharmaceutical Interventions to Mitigate the Spread of SARS-CoV-2: Results From a Survey in the Swiss General Adult Population. <i>Frontiers in Public Health</i> , 2022, 10, 828584.	1.3	2
992	E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces. <i>PeerJ</i> , 2022, 10, e13099.	0.9	3
993	Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity. <i>Frontiers in Immunology</i> , 2022, 13, 830433.	2.2	12
994	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
995	[Translated article] COVID-19 in Youth and the Fifth Wave. <i>Archivos De Bronconeumologia</i> , 2022, 58, T213-T214.	0.4	2
997	Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. <i>Microbiology Spectrum</i> , 2022, 10, e0225221.	1.2	9
998	Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0048221.	1.8	21

#	ARTICLE	IF	CITATIONS
999	Dynamical regulations on mobility and vaccinations for controlling COVID-19 spread. Scientific Reports, 2022, 12, 3554.	1.6	1
1000	Efficacy of approved vaccines to prevent COVID-19: a systematic review and network meta-analysis of reconstructed individual patient data from randomized trials. Zeitschrift Fur Gesundheitswissenschaften, 2022, , 1-10.	0.8	3
1001	Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral) Tj ETQq0 0 0 rgBT /Overlock 10 Tf healthcare workers. Infection Control and Hospital Epidemiology, 2023, 44, 75-81.	1.0	9
1002	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
1003	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohnâ€™s Disease. Frontiers in Medicine, 2022, 9, 795889.	1.2	1
1004	Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2022, 226, 1224-1230.	1.9	13
1005	Data-Driven Prediction for COVID-19 Severity in Hospitalized Patients. International Journal of Environmental Research and Public Health, 2022, 19, 2958.	1.2	4
1006	A Shot in the Arm for Vaccination Intention: The Media and the Health Belief Model in Three Chinese Societies. International Journal of Environmental Research and Public Health, 2022, 19, 3705.	1.2	8
1007	Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic. Genes, 2022, 13, 552.	1.0	13
1009	Role of the Microbiome in the Pathogenesis of COVID-19. Frontiers in Cellular and Infection Microbiology, 2022, 12, 736397.	1.8	17
1010	COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2.1	2.1	9
1011	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. JAMA - Journal of the American Medical Association, 2022, 327, 1032.	3.8	57
1013	Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. International Journal of Infectious Diseases, 2022, 119, 69-76.	1.5	48
1014	Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs. Biomedicines, 2022, 10, 594.	1.4	6
1015	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	1.8	117
1016	Population Attributable Fractions of Underlying Medical Conditions for Coronavirus Disease 2019 (COVID-19) Diagnosis and COVID-19 Hospitalizations, Ventilations, and Deaths Among Adults in the United States. Open Forum Infectious Diseases, 2022, 9, ofac099.	0.4	9
1017	Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16â€“29Â years. Vaccine, 2022, 40, 2781-2789.	1.7	14
1019	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. Immunogenetics, 2022, 74, 381-407.	1.2	5

#	ARTICLE	IF	CITATIONS
1020	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 801870.	2.0	13
1021	Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern. <i>IScience</i> , 2022, 25, 103968.	1.9	14
1022	Review of component designs for post-COVID-19 HVAC systems: possibilities and challenges. <i>Heliyon</i> , 2022, 8, e09001.	1.4	6
1023	Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. <i>Clinical Infectious Diseases</i> , 2022, 75, e564-e571.	2.9	39
1024	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.	13.9	215
1025	A Visualization Analysis of Crisis and Risk Communication Research Using CiteSpace. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2923.	1.2	20
1026	Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. <i>Lancet, The</i> , 2022, 399, 1254-1264.	6.3	47
1027	The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine. <i>Vaccines</i> , 2022, 10, 536.	2.1	14
1028	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
1029	Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19. <i>Frontiers in Medicine</i> , 2022, 9, 809154.	1.2	8
1030	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
1031	Dynamic observation of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID-19 vaccination. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24325.	0.9	7
1032	Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile. <i>Frontiers in Public Health</i> , 2022, 10, 797569.	1.3	2
1033	China's COVID-19 Control Strategy and Its Impact on the Global Pandemic. <i>Frontiers in Public Health</i> , 2022, 10, 857003.	1.3	28
1034	The Third Wave: Comparing Seasonal Trends in COVID-19 Patient Data at a Large Hospital System in New York City. , 2022, 4, e0653.		17
1035	Co-Administration of Menstrual Blood-Derived Stem Cells and Remdesivir for the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Induced Pneumonia: A Research Protocol. , 2022, 6, 1-12.		1
1036	Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13152.	1.3	5
1037	Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida. <i>Clinical Infectious Diseases</i> , 2022, 75, 1618-1627.	2.9	4

#	ARTICLE	IF	CITATIONS
1038	Unvaccinated Children Are an Important Link in the Transmission of SARS-CoV-2 Delta Variant (B1.617.2): Comparative Clinical Evidence From a Recent Community Surge. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 814782.	1.8	9
1040	The Effects of Media Encouragements on Coronavirus Vaccination Decision and Public Interest in Traveling Abroad. <i>Information (Switzerland)</i> , 2022, 13, 157.	1.7	2
1041	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
1042	Global trends in COVID-19. , 2022, 1, 31-39.		8
1043	Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	12
1045	Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan. <i>Vaccines</i> , 2022, 10, 430.	2.1	22
1047	Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England. <i>EClinicalMedicine</i> , 2022, 45, 101319.	3.2	8
1048	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
1049	Patients After Orthotopic Heart Transplantation With COVID-19: Are We Fast Enough With Vaccinations?. <i>Transplantation Proceedings</i> , 2022, 54, 897-900.	0.3	0
1053	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. <i>RNA Biology</i> , 2022, 19, 386-410.	1.5	19
1054	Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. <i>Journal of Medical Virology</i> , 2022, 94, 3063-3069.	2.5	7
1055	Demographic, Health and Pandemic-Related Determinants of COVID-19 Vaccination Intention Among Filipino Emerging Adults. <i>Emerging Adulthood</i> , 2022, 10, 815-820.	1.4	11
1056	Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. <i>MBio</i> , 2022, 13, e0361721.	1.8	67
1057	COVID-19 vaccination in cancer patients: a narrative review. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210861.	0.4	9
1058	Prevalence and patterns of facemask use in marketplaces in Addis Ababa: Implications for targeted SARS-CoV-2 risk communication. <i>Cogent Social Sciences</i> , 2022, 8, .	0.5	0
1059	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
1061	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. <i>Scientific Reports</i> , 2022, 12, 5207.	1.6	8
1063	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10

#	ARTICLE	IF	CITATIONS
1064	Individual Preferences for COVID-19 Vaccination under the China's 2021 National Vaccination Policy: A Discrete Choice Experiment Study. <i>Vaccines</i> , 2022, 10, 543.	2.1	6
1066	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. <i>Inflammation Research</i> , 2022, 71, 377-396.	1.6	11
1067	Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2. <i>PLoS Computational Biology</i> , 2022, 18, e1009978.	1.5	10
1068	Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2022, 22, 270.	1.3	8
1069	SARS-CoV-2 Omicron variant: Immune escape and vaccine development. <i>MedComm</i> , 2022, 3, e126.	3.1	74
1070	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>Vaccines</i> , 2022, 10, 479.	2.1	9
1072	Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India. <i>International Journal of Infectious Diseases</i> , 2022, 119, 111-113.	1.5	1
1073	Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021. <i>Pediatrics</i> , 2022, 149, .	1.0	51
1074	Aspirin in COVID-19: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2022, 13, 849628.	1.6	10
1075	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
1076	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	7
1077	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
1078	Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2. <i>JAMA Network Open</i> , 2022, 5, e223064.	2.8	21
1079	Optimizing COVID-19 vaccination programs during vaccine shortages. <i>Infectious Disease Modelling</i> , 2022, 7, 286-298.	1.2	26
1081	RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant. <i>Emerging Microbes and Infections</i> , 2022, 11, 978-987.	3.0	17
1082	Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. <i>JAMA Network Open</i> , 2022, 5, e220935.	2.8	20
1083	Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 384-392.	2.7	43
1087	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5

#	ARTICLE	IF	CITATIONS
1088	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
1090	Timely Monitoring COVID-19 Vaccine Protection, Berlin, Germany, April 15th to December 15th, 2021. <i>International Journal of Public Health</i> , 2022, 67, 1604633.	1.0	0
1091	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. <i>EClinicalMedicine</i> , 2022, 45, 101326.	3.2	29
1092	Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy. <i>EClinicalMedicine</i> , 2022, 46, 101360.	3.2	17
1093	Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave. <i>Preventive Medicine Reports</i> , 2022, 26, 101752.	0.8	8
1095	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
1096	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
1097	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
1098	Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.3	1
1099	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1
1100	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
1101	Pathogen Species Is Associated With Mortality in Nosocomial Bloodstream Infection in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
1102	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
1103	High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. <i>Nature Communications</i> , 2022, 13, 1726.	5.8	5
1104	Nature's contributions in coping with a pandemic in the 21st century: A narrative review of evidence during COVID-19. <i>Science of the Total Environment</i> , 2022, 833, 155095.	3.9	68
1105	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. <i>Vaccine</i> , 2022, 40, 2848-2855.	1.7	7
1106	The Impact of COVID-19 on Mortality in Italy: Retrospective Analysis of Epidemiological Trends. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e36022.	1.2	12
1107	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22

#	ARTICLE	IF	CITATIONS
1108	Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100227.	1.5	8
1109	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
1110	The COVID-19 vaccine concerns scale: Development and validation of a new measure. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	6
1111	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. <i>Clinical Immunology</i> , 2022, 238, 108999.	1.4	10
1112	The Need for Pre-vaccination Screening. <i>International Journal of Infection</i> , 2022, In Press, .	0.4	0
1113	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e252-e264.	3.4	29
1114	Combatting future variants of SARS-CoV-2 using an in-silico peptide vaccine approach by targeting the spike protein. <i>Medical Hypotheses</i> , 2022, 161, 110810.	0.8	5
1115	First Detection of SARS-CoV-2 B.1.617.2 (Delta) Variant of Concern in a Symptomatic Cat in Spain. <i>Frontiers in Veterinary Science</i> , 2022, 9, 841430.	0.9	16
1117	Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4050.	1.8	17
1118	Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. <i>Science Translational Medicine</i> , 2022, 14, eabm0899.	5.8	68
1119	Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>Transplantation</i> , 2022, 106, 1430-1439.	0.5	18
1120	Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 781-790.	4.6	191
1121	Genetic Surveillance of Five SARS-CoV-2 Clinical Samples in Henan Province Using Nanopore Sequencing. <i>Frontiers in Immunology</i> , 2022, 13, 814806.	2.2	5
1122	Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design. <i>Frontiers in Immunology</i> , 2022, 13, 832106.	2.2	7
1124	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
1125	Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. <i>Journal of Controlled Release</i> , 2022, 344, 80-96.	4.8	92
1126	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 499-502.	1.0	10
1127	A global picture: therapeutic perspectives for COVID-19. <i>Immunotherapy</i> , 2022, 14, 351-371.	1.0	56

#	ARTICLE	IF	CITATIONS
1130	Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112843.	2.5	14
1131	Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100212.	1.5	17
1132	Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. <i>Journal of Theoretical Biology</i> , 2022, 540, 111063.	0.8	75
1133	Agent-based epidemiological modeling of COVID-19 in localized environments. <i>Computers in Biology and Medicine</i> , 2022, 144, 105396.	3.9	6
1134	The interconnection between independent reactive control policies drives the stringency of local containment. <i>Chaos, Solitons and Fractals</i> , 2022, 158, 112012.	2.5	1
1135	Indiscriminate SARS-CoV-2 multivariant detection using magnetic nanoparticle-based electrochemical immunosensing. <i>Talanta</i> , 2022, 243, 123356.	2.9	29
1136	Generalizability assessment of COVID-19 3D CT data for deep learning-based disease detection. <i>Computers in Biology and Medicine</i> , 2022, 145, 105464.	3.9	11
1137	Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients. <i>Infection, Genetics and Evolution</i> , 2022, 100, 105278.	1.0	2
1138	Machine learning prediction of 3CL SARS-CoV-2 docking scores. <i>Computational Biology and Chemistry</i> , 2022, 98, 107656.	1.1	9
1139	Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159139.	1.2	18
1140	High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries. <i>Travel Medicine and Infectious Disease</i> , 2022, 48, 102321.	1.5	6
1141	The Influence of SARS-CoV-2 Variants on National Case-Fatality Rates: Correlation and Validation Study. <i>Jmirx Med</i> , 2022, 3, e32935.	0.2	9
1142	Effectiveness and Safety of COVID-19 Vaccine. <i>Trends in the Sciences</i> , 2021, 26, 10_18-10_25.	0.0	0
1145	Why we still need drugs for COVID-19 and can't just rely on vaccines. <i>Respirology</i> , 2022, 27, 109-111.	1.3	8
1148	A Web-based Method for Designing and Validating Primer-probe Sets for SARS-CoV-2. , 2021, , .		0
1151	Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 3-5.	2.2	1
1152	Vaccination against COVID-19 in Ukraine. Safety of Vaccines. <i>Ukraïnskij Žurnal Medicini Bã-ologã-Ta Sportu</i> , 2021, 6, 200-206.	0.0	0
1153	The COVID-19 surge in Indonesia: what we learned and what to expect. <i>Breathe</i> , 2021, 17, 210146.	0.6	4

#	ARTICLE	IF	CITATIONS
1154	Pases sanitarios para COVID-19. Cuadernos Filosóficos / Segunda Época, 2021, , .	0.0	0
1155	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
1156	Status and perception toward the COVID-19 vaccine: A cross-sectional online survey among adult population of Bangladesh. <i>Health Science Reports</i> , 2021, 4, e451.	0.6	12
1157	ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. <i>Endoscopy</i> , 2022, 54, 211-216.	1.0	12
1159	Epidemiology and Vaccine Efficacy of Delta Variant. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 56-58.	0.1	0
1160	Vaccinations, Mobility and COVID-19 Transmission. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 97.	1.2	16
1161	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
1163	Follow-up CT of reversed halo sign in SARS-CoV-2 delta VOC pneumonia: A report of two cases. <i>Journal of Medical Virology</i> , 2022, 94, 1289-1291.	2.5	2
1164	Clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant. <i>Medicine (United States)</i> , 2021, 100, e28184.	0.4	4
1165	Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. <i>Cell and Bioscience</i> , 2021, 11, 199.	2.1	26
1166	A Narrative Review of COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 62.	2.1	40
1167	Civility, Trust, and Responding to Echo Chambers. <i>Dialogue-Canadian Philosophical Review</i> , 2021, 60, 403-413.	0.1	0
1168	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
1170	Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant. <i>PLoS Computational Biology</i> , 2021, 17, e1009629.	1.5	17
1171	Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	2
1172	HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. <i>Cell Reports</i> , 2021, 37, 110167.	2.9	18
1173	Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0165921.	1.2	2
1176	Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies. <i>Viruses</i> , 2021, 13, 2546.	1.5	7

#	ARTICLE	IF	CITATIONS
1177	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	1.5	19
1178	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
1179	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. <i>Frontiers in Immunology</i> , 2021, 12, 789905.	2.2	7
1180	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. <i>Frontiers in Public Health</i> , 2021, 9, 751451.	1.3	9
1181	COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study. <i>Vaccines</i> , 2022, 10, 17.	2.1	16
1183	Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5363-5373.	1.1	8
1184	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. <i>Cells</i> , 2022, 11, 67.	1.8	7
1185	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
1187	Treatment and outcome of COVID-19 patients in a specialized hospital during the third wave: advance of age and increased mortality compared with the first/second waves. <i>JA Clinical Reports</i> , 2021, 7, 85.	0.2	6
1189	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
1190	Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021. <i>Vaccines</i> , 2021, 9, 1489.	2.1	18
1192	Discovering spatiotemporal patterns of COVID-19 pandemic in South Korea. <i>Scientific Reports</i> , 2021, 11, 24470.	1.6	20
1193	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Vaccines</i> , 2022, 10, 23.	2.1	37
1195	Shifting our stance for current COVID-19 outbreaks: A global response to an international pandemic. <i>Journal of Global Health</i> , 2021, 11, 03123.	1.2	0
1198	Why promoting a COVID-19 vaccine booster dose?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100967.	0.6	18
1199	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
1203	The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China. <i>Infectious Diseases of Poverty</i> , 2021, 10, 140.	1.5	13
1204	Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 Januaryâ€“2 July 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e267-e275.	2.9	12

#	ARTICLE	IF	CITATIONS
1205	The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05028.	1.2	4
1206	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. <i>Vaccines</i> , 2022, 10, 37.	2.1	15
1208	Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. <i>Frontiers in Immunology</i> , 2021, 12, 793191.	2.2	16
1211	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. , 2021, , .		5
1216	Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study. <i>Vaccines</i> , 2021, 9, 1461.	2.1	58
1217	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
1218	Which vaccination strategy against COVID-19?. <i>International Health</i> , 2023, 15, 150-160.	0.8	0
1219	Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. <i>Clinical and Translational Immunology</i> , 2022, 11, e1388.	1.7	20
1220	Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers. <i>Journal of Korean Medical Science</i> , 2022, 37, e135.	1.1	6
1221	Challenges of coronavirus disease 2019 (COVID-19) in Lebanon in the midst of the economic collapse. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.2	5
1222	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 34.	0.3	5
1223	Computational characterization of the behavior of a saliva droplet in a social environment. <i>Scientific Reports</i> , 2022, 12, 6405.	1.6	7
1224	De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study. <i>Vaccine</i> , 2022, 40, 3165-3173.	1.7	4
1226	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
1227	Epidemiological Characteristics of the COVID-19 Pandemic During the First and Second Waves in Chhattisgarh, Central India: A Comparative Analysis. <i>Cureus</i> , 2022, 14, e24131.	0.2	5
1228	Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4586.	1.2	63
1229	Outbreak of delta variant SARS-CoV-2 virus on a psychogeriatric ward in Helsinki, Finland, August 2021; two-dose vaccination reduces mortality and disease severity amongst the elderly.. <i>Epidemiology and Infection</i> , 2022, , 1-14.	1.0	0
1230	Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). <i>Clinical Infectious Diseases</i> , 2022, 75, 1971-1979.	2.9	12

#	ARTICLE	IF	CITATIONS
1232	Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland. , 2022, 152, .		3
1233	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. Scientific Reports, 2022, 12, 6241.	1.6	12
1234	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. JAMA Network Open, 2022, 5, e227038.	2.8	23
1235	Advanced Functions Embedded in the Second Version of Database, Global Evaluation of SARS-CoV-2/hCoV-19 Sequences 2. Frontiers in Medicine, 2022, 9, 813964.	1.2	0
1236	How the COVID 19 pandemic will shape influenza public health initiatives: The UK experience. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	1.4	7
1237	Association of Online Search Trends With Vaccination in the United States: June 2020 Through May 2021. Frontiers in Immunology, 2022, 13, 884211.	2.2	4
1238	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. Viruses, 2022, 14, 827.	1.5	14
1239	COVID-19 vaccine hesitancy: Considerations for reluctance and improving vaccine uptake. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	1.4	13
1240	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
1241	Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infectious Diseases, The, 2022, 22, 990-1001.	4.6	16
1242	SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Journal of Medical Virology, 2022, 94, 3768-3775.	2.5	13
1243	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
1244	Investigating the Extent of Primer Dropout in SARS-CoV-2 Genome Sequences During the Early Circulation of Delta Variants. Frontiers in Virology, 2022, 2, .	0.7	14
1245	COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimer's and Dementia, 2023, 19, 421-432.	0.4	26
1246	Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. Viruses, 2022, 14, 802.	1.5	30
1247	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Vaccines, 2022, 10, 591.	2.1	27
1248	Evaluation of the effects of meteorological factors on COVID-19 prevalence by the distributed lag nonlinear model. Journal of Translational Medicine, 2022, 20, 170.	1.8	12
1249	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases, 2022, 9, .	0.4	62

#	ARTICLE	IF	CITATIONS
1251	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100381.	3.0	15
1252	Epidemiological analysis of SARS-CoV-2 B.1.617.2 (delta variant) transmission in an educational institute. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.3	0
1253	Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy. <i>IScience</i> , 2022, 25, 104223.	1.9	58
1255	SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021: Children Susceptible and Vaccination Breakthrough Infection. <i>Frontiers in Microbiology</i> , 2022, 13, 856757.	1.5	10
1256	Crowding and vaccination: Tourist's two-sided perception on crowding and the moderating effect of vaccination status during COVID-19 pandemic. <i>Journal of Destination Marketing & Management</i> , 2022, 24, 100705.	3.4	7
1257	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, 1980-1992.	2.9	92
1258	Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students. <i>JAMA Pediatrics</i> , 2022, 176, 679.	3.3	11
1259	Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant. <i>JAMA Network Open</i> , 2022, 5, e228071.	2.8	11
1260	SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination. <i>Viruses</i> , 2022, 14, 814.	1.5	2
1261	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0000822.	1.2	17
1263	The need for linked genomic surveillance of SARS-CoV-2. <i>Canada Communicable Disease Report</i> , 2022, 48, 131-139.	0.6	13
1264	Risk of sustained SARS-CoV-2 transmission in Queensland, Australia. <i>Scientific Reports</i> , 2022, 12, 6309.	1.6	5
1265	Covax-19/Spikogen [®] vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. <i>Vaccine</i> , 2022, 40, 3182-3192.	1.7	25
1266	COVID-19 Vaccination and Estimated Public Health Impact in California. <i>JAMA Network Open</i> , 2022, 5, e228526.	2.8	15
1267	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. <i>EBioMedicine</i> , 2022, 78, 103944.	2.7	119
1268	Humoral and cellular responses to spike of $\hat{\Gamma}$ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. <i>International Journal of Infectious Diseases</i> , 2022, 121, 24-30.	1.5	21
1269	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
1270	Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura. <i>Platelets</i> , 2022, 33, 652-653.	1.1	6

#	ARTICLE	IF	CITATIONS
1271	COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2. <i>Science Advances</i> , 2022, 8, eabm3624.	4.7	10
1272	Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa. <i>International Journal of Health Services</i> , 2022, 52, 323-329.	1.2	10
1273	SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection. <i>PLoS ONE</i> , 2022, 17, e0266701.	1.1	11
1274	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
1276	Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario.. <i>Archives of Razi Institute</i> , 2021, 76, 1165-1174.	0.4	7
1277	COVID-19 Delta variation; more contagious or more pernicious?. <i>Acta Biomedica</i> , 2022, 92, e2021454.	0.2	2
1278	Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.. <i>Acta Biomedica</i> , 2022, 93, e2022179.	0.2	9
1279	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.2	0
1280	BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients. <i>Transplant International</i> , 2022, 35, 10239.	0.8	17
1281	Vaccine Breakthrough Infections of SARS-Cov-2: A Case Report.. <i>Ethiopian Journal of Health Sciences</i> , 2022, 32, 201-204.	0.2	0
1282	Repairing our broken relationship with the vaccine hesitant. <i>Canadian Family Physician</i> , 2022, 68, 211-213.	0.1	4
1283	Online public interest in common malignancies and cancer screening during the COVID-19 pandemic in the United States.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 723-732.	0.3	3
1284	Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model. <i>Age and Ageing</i> , 2022, 51, .	0.7	6
1286	Antibody Responses Elicited by mRNA Vaccination in Firefighters Persist Six Months and Correlate Inversely with Age and Directly with BMI. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1287	Relationship between blood clots and COVID-19 vaccines: A literature review. <i>Open Life Sciences</i> , 2022, 17, 401-415.	0.6	6
1288	Theoretical Analysis of the SIRVVD Model for Insights Into the Target Rate of COVID-19/SARS-CoV-2 Vaccination in Japan. <i>IEEE Access</i> , 2022, 10, 43044-43054.	2.6	2
1290	Humoral immunity against SARSâ€CoVâ€2 variants including omicron in solid organ transplant recipients after three doses of a COVIDâ€19 mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, e1391.	1.7	21
1291	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24

#	ARTICLE	IF	CITATIONS
1292	Exploratory Data Analysis on SARS-CoV-2 Variants in India: especially Omicron (B.1.1.529) as of 6th December 2021. , 2022, , .		1
1293	Efficient Framework for Detection of COVID-19 Omicron and Delta Variants Based on Two Intelligent Phases of CNN Models. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-10.	0.7	17
1294	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. Frontiers in Immunology, 2022, 13, 804945.	2.2	12
1295	Variant-specific vaccination induces systems immune responses and potent inÂvivo protection against SARS-CoV-2. Cell Reports Medicine, 2022, 3, 100634.	3.3	10
1296	The impact of shifting demographics, variants of concern and vaccination on outcomes during the first 3 COVID-19 waves in Alberta and Ontario: a retrospective cohort study. CMAJ Open, 2022, 10, E400-E408.	1.1	16
1298	Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program. Viruses, 2022, 14, 847.	1.5	11
1299	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Vaccines, 2022, 10, 702.	2.1	18
1300	Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2201433119.	3.3	19
1301	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. Npj Vaccines, 2022, 7, 49.	2.9	7
1304	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. Future Virology, 2022, 17, 403-413.	0.9	6
1305	Covid-19 in children aged 5â€“11: Examining the issues surrounding vaccination and public health policy. Paediatric Respiratory Reviews, 2022, , .	1.2	3
1306	Covid-19-Ausbruch mit Durchbruchinfektionen wÃ¤hrend einer Jugendreise nach DÃnemark im Juli 2021 mit der Delta-Untervariante AY.6. Gesundheitswesen, 2022, 84, .	0.8	0
1307	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10
1308	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines, 2022, 10, 712.	2.1	4
1309	Effectiveness of Messenger RNAâ€“based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clinical Infectious Diseases, 2022, 75, 2186-2192.	2.9	12
1310	Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity. Viruses, 2022, 14, 868.	1.5	6
1311	COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S). Osong Public Health and Research Perspectives, 2022, 13, 114-122.	0.7	1
1312	Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. Frontiers in Immunology, 2022, 13, 869990.	2.2	40

#	ARTICLE	IF	CITATIONS
1313	A combination of potentially neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. <i>PLoS Pathogens</i> , 2022, 18, e1010465.	2.1	8
1314	COVID-19 in pediatric kidney transplantation: a follow-up report of the Improving Renal Outcomes Collaborative. <i>Pediatric Nephrology</i> , 2023, 38, 537-547.	0.9	7
1315	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. <i>Med</i> , 2022, 3, 406-421.e4.	2.2	17
1316	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	1.2	3
1317	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
1318	The cost-effectiveness of standalone HEPA filtration units for the prevention of airborne SARS CoV-2 transmission. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, 22.	0.6	3
1319	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
1320	Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: A comparative genomics study at the peak of the third wave in Bogota, Colombia. <i>Journal of Medical Virology</i> , 2022, , .	2.5	4
1321	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
1322	Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain. <i>Journal of Molecular Biology</i> , 2022, 434, 167622.	2.0	3
1323	Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 736.	2.1	17
1325	SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan. <i>PLoS ONE</i> , 2022, 17, e0263700.	1.1	0
1326	An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply. <i>PLoS ONE</i> , 2022, 17, e0265957.	1.1	2
1327	Effectiveness of Ad26.CO2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 2243-2245.	13.9	65
1328	Favipiravir for treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
1329	COVID-19 vaccination challenges: A mini-review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	5
1330	The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. <i>Scientific Reports</i> , 2022, 12, 7493.	1.6	8
1331	HRCT Chest in Patients Suffering from COVID-19: Experience from a Tertiary Care Centre in India During Second Wave of the Pandemic. <i>Imaging</i> , 2022, , .	0.3	1

#	ARTICLE	IF	CITATIONS
1332	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. <i>Frontiers in Immunology</i> , 2022, 13, 879036.	2.2	13
1334	Covid-19 vaccine immunogenicity in people living with HIV-1. <i>Vaccine</i> , 2022, 40, 3633-3637.	1.7	47
1336	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
1337	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. <i>Science Immunology</i> , 2022, 7, eabp8328.	5.6	40
1338	Measuring vaccine effectiveness from limited public health datasets: Framework and estimates from India's second COVID wave. <i>Science Advances</i> , 2022, 8, eabn4274.	4.7	1
1339	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
1340	Trends and Correlates of Breakthrough Infections With SARS-CoV-2. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	5
1341	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
1342	Illness Characteristics of COVID-19 in Children Infected with the SARS-CoV-2 Delta Variant. <i>Children</i> , 2022, 9, 652.	0.6	28
1343	SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity. <i>Journal of Chemical Information and Modeling</i> , 2022, , .	2.5	5
1344	Impact of national Covid-19 vaccination Campaign, South Korea. <i>Vaccine</i> , 2022, 40, 3670-3675.	1.7	21
1345	Vaccines for Covid-19: An insight on their effectiveness and adverse effects. <i>Journal of Medical Virology</i> , 2022, , .	2.5	7
1346	Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 103, 115720.	0.8	2
1347	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. <i>New England Journal of Medicine</i> , 2022, 386, 2097-2111.	13.9	147
1349	Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. <i>Nature Communications</i> , 2022, 13, 2494.	5.8	22
1350	Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines. <i>International Journal of Audiology</i> , 2023, 62, 587-591.	0.9	12
1351	Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). <i>World Allergy Organization Journal</i> , 2022, 15, 100653.	1.6	12
1352	Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. <i>Science Immunology</i> , 2022, 7, eabo3425.	5.6	28

#	ARTICLE	IF	CITATIONS
1353	A Review of Different Vaccines and Strategies to Combat COVID-19. <i>Vaccines</i> , 2022, 10, 737.	2.1	8
1354	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	3
1355	Understanding the spatial diffusion dynamics of the COVID-19 pandemic in the city system in China. <i>Social Science and Medicine</i> , 2022, 302, 114988.	1.8	1
1356	Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. <i>The Lancet Global Health</i> , 2022, 10, e798-e806.	2.9	141
1357	Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35311.	1.2	13
1358	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. <i>PLoS ONE</i> , 2022, 17, e0267824.	1.1	15
1359	Lethal synergy between SARS-CoV-2 and <i>Streptococcus pneumoniae</i> in hACE2 mice and protective efficacy of vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	14
1360	Effective mathematical modelling of health passes during a pandemic. <i>Scientific Reports</i> , 2022, 12, 6989.	1.6	4
1361	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
1362	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
1363	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
1364	Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. <i>Npj Vaccines</i> , 2022, 7, 52.	2.9	9
1365	Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. <i>International Journal of Medical Sciences</i> , 2022, 19, 834-841.	1.1	4
1367	Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	13
1368	Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. <i>American Journal of Transplantation</i> , 2022, 22, 2228-2236.	2.6	24
1369	Statistical Challenges in Tracking the Evolution of SARS-CoV-2. <i>Statistical Science</i> , 2022, 37, .	1.6	7
1370	The Impacts of Gradually Terminating Nonpharmaceutical Interventions for SARS-CoV-2: A Mathematical Modelling Analysis. <i>Fundamental Research</i> , 2022, , .	1.6	0
1371	SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC). <i>Scientific Reports</i> , 2022, 12, 8074.	1.6	5

#	ARTICLE	IF	CITATIONS
1372	Appropriate relaxation of non-pharmaceutical interventions minimizes the risk of a resurgence in SARS-CoV-2 infections in spite of the Delta variant. <i>PLoS Computational Biology</i> , 2022, 18, e1010054.	1.5	3
1373	Being a Public Health Statistician During a Global Pandemic. <i>Statistical Science</i> , 2022, 37, .	1.6	4
1374	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
1375	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 24, 100474.	1.3	13
1376	Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be <i>Ex Vivo</i> ?. <i>Expert Review of Vaccines</i> , 2022, 21, 1111-1120.	2.0	8
1377	Public health impact of covid-19 vaccines in the US: observational study. <i>BMJ, The</i> , 2022, 377, e069317.	3.0	102
1378	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345.	0.8	2
1379	An assessment of the vaccination of school-aged children in England against SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 196.	2.3	9
1380	Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. <i>PLoS ONE</i> , 2022, 17, e0268797.	1.1	13
1381	The roles of inactivated vaccines in older patients with infection of Delta variant in Nanjing, China. <i>Aging</i> , 2022, 14, 4211-4219.	1.4	3
1382	Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care.. <i>Acta Biomedica</i> , 2022, 93, e2022182.	0.2	3
1383	Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
1384	Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients. <i>Lung India</i> , 2022, 39, 305.	0.3	0
1385	Prolonged Diarrhea Following COVID-19 Vaccination: A Case Report and Literature Review. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 257, 251-259.	0.5	5
1386	Dispelling the Myth of a Pandemic of the Unvaccinated. , 2021, 2, 267-286.		0
1390	COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties. <i>Lancet Oncology, The</i> , 2022, 23, 693-695.	5.1	5
1391	Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	2.9	23
1393	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3

#	ARTICLE	IF	CITATIONS
1395	Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
1396	Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. <i>Lancet Oncology</i> , The, 2022, 23, 748-757.	5.1	60
1397	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
1398	Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution. <i>PLoS ONE</i> , 2022, 17, e0268389.	1.1	7
1399	A log-odds system for waning and boosting of COVID-19 vaccine effectiveness. <i>Vaccine</i> , 2022, , .	1.7	10
1400	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	9
1401	Association of Social-Cognitive Factors with Individual Preventive Behaviors of COVID-19 among a Mixed-Sample of Older Adults from China and Germany. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6364.	1.2	6
1402	The suitability and usability of a tool to assess contact status from COVID-19 exposures in the workplace. <i>Australian and New Zealand Journal of Public Health</i> , 2022, 46, 511-516.	0.8	0
1403	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	4.3	54
1404	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
1405	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
1406	Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	53
1407	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. <i>EBioMedicine</i> , 2022, 80, 104073.	2.7	28
1408	Assessing the Effectiveness of COVID-19 Vaccines in Pakistan: A Test-Negative Case-Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1409	Mental health outcome among psychiatric patients due to COVID 19 lockdown induced disruption of access to psychiatric services: A cross-sectional study. <i>Telangana Journal of Psychiatry</i> , 2022, 8, 7.	0.0	2
1410	An Epidemic Model for SARS-CoV-2 with Self-adaptive Containment Measures. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1411	COVID-19 in Amazonia, Brazil: How Will We Eradicate Severe Cases of COVID-19?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1414	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16

#	ARTICLE	IF	CITATIONS
1415	New Wave of COVID-19 Vaccine Opinions in the Month the 3rd Booster Dose Arrived. <i>Vaccines</i> , 2022, 10, 881.	2.1	8
1416	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. <i>Cancer Cell</i> , 2022, 40, 738-753.e5.	7.7	19
1418	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
1419	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
1420	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 81.	0.9	15
1421	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 931-933.	4.6	133
1422	Longitudinal dynamics of SARS-CoV-2 anti-receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 122, 174-177.	1.5	5
1423	Control of COVID-19 Outbreaks under Stochastic Community Dynamics, Bimodality, or Limited Vaccination. <i>Advanced Science</i> , 2022, 9, .	5.6	9
1424	VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. <i>Bioinformatics</i> , 2022, 38, 3549-3556.	1.8	4
1425	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ</i> , The, 0, , e069989.	3.0	78
1426	Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
1427	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
1429	Commentary: Reimagining Community Mental Health Care Services: Case Study of a Need Based Biopsychosocial Response Initiated During Pandemic. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	0
1430	Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism. <i>Npj Vaccines</i> , 2022, 7, .	2.9	6
1431	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
1432	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
1433	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
1434	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6123.	1.8	9

#	ARTICLE	IF	CITATIONS
1435	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
1436	Two Separate Clusters of SARS-CoV-2 Delta Variant Infections in a Group of 41 Students Travelling from India: An Illustration of the Need for Rigorous Testing and Quarantine. <i>Viruses</i> , 2022, 14, 1198.	1.5	4
1437	Effects of Vaccination and the Spatio-temporal Diffusion of Covid-19 Incidence in Turkey. <i>Geographical Analysis</i> , 2023, 55, 399-426.	1.9	2
1439	Severity of COVID-19 after Vaccination among Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 843-850.	2.2	34
1440	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
1441	Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
1442	Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine. <i>Journal of Immunological Methods</i> , 2022, 506, 113293.	0.6	4
1443	Mapping of SARS-CoV-2 spike protein evolution during the first and second waves of COVID-19 infections in India. <i>Future Virology</i> , 2022, 17, 557-575.	0.9	2
1444	Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
1446	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
1447	Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories. <i>Nature Communications</i> , 2022, 13, .	5.8	59
1448	SARS-CoV-2 Delta variant isolates from vaccinated individuals. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
1449	The correlation study on chest CT features and kidney injury in severe COVID-19 pneumonia from a multicenter cohort study. <i>Chinese Journal of Academic Radiology</i> , 0, , .	0.4	1
1450	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
1451	COVID-19 vaccine distribution planning using a congested queuing system—A real case from Australia. <i>Transportation Research, Part E: Logistics and Transportation Review</i> , 2022, 163, 102749.	3.7	22
1452	Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults. <i>Journal of Clinical Virology</i> , 2022, 152, 105193.	1.6	12
1453	Highly sensitive electrochemical aptasensor for SARS-CoV-2 antigen detection based on aptamer-binding induced multiple hairpin assembly signal amplification. <i>Talanta</i> , 2022, 248, 123605.	2.9	19
1454	Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021. <i>Global Epidemiology</i> , 2022, 4, 100076.	0.6	8

#	ARTICLE	IF	CITATIONS
1455	Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	15
1456	Impact of Perceptions and Attitudes on Air Travel Choices in the Post-COVID-19 Era: A Cross-National Analysis of Stated Preference Data. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1457	Long Term Vaccination Strategies to Mitigate the Global Impact of SARS-CoV-2 Transmission: A Modelling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1458	COVID-19 Deaths in Children and Young People: Active Prospective National Surveillance, March 2020 to December 2021, England. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1459	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
1460	SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. <i>Sensors & Diagnostics</i> , 2022, 1, 851-866.	1.9	3
1461	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 874.	2.1	5
1463	Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	22
1464	Biological Determinants of Emergence of SARS-CoV-2 Variants. , 0, , .		0
1465	Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021â€“November 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e469-e476.	2.9	9
1466	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (Juneâ€“July 2021). <i>Vaccines</i> , 2022, 10, 984.	2.1	10
1467	The Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations During the Delta Wave: A Patient-Population Study at a Major Referral Center. <i>Cureus</i> , 2022, , .	0.2	0
1468	Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?. <i>Vacunas</i> , 2022, 23, S121-S122.	1.1	0
1470	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
1471	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
1472	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. <i>Vaccines</i> , 2022, 10, 904.	2.1	7
1473	Household Secondary Transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant From a Community Cluster in a Nursery in Japan. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	1
1474	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6â€“17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 2212-2225.	6.3	23

#	ARTICLE	IF	CITATIONS
1475	Behavioural determinants of COVID-19 vaccination acceptance among healthcare workers: a rapid review. <i>Public Health</i> , 2022, 210, 123-133.	1.4	19
1476	COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination. <i>Journal of the Royal Society Interface</i> , 2022, 19, .	1.5	60
1477	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
1478	The association between social media use and hesitancy toward COVID-19 vaccine booster shots in China: A web-based cross-sectional survey. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	19
1479	SARS-CoV-2 antibody prevalence in a pediatric cohort of unvaccinated children in Mérida, Yucatán, México. <i>PLOS Global Public Health</i> , 2022, 2, e0000354.	0.5	0
1480	Correlation between Population Density and COVID-19 Cases during the Third Wave in Malaysia: Effect of the Delta Variant. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7439.	1.2	16
1481	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
1482	Addressing COVID-19 vaccine hesitancy. <i>Drugs in Context</i> , 0, 11, 1-19.	1.0	11
1483	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
1484	Advancements in Testing Strategies for COVID-19. <i>Biosensors</i> , 2022, 12, 410.	2.3	8
1485	Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. <i>PLoS ONE</i> , 2022, 17, e0269032.	1.1	4
1486	The effectiveness of various control strategies: an insight from a comparison modelling study. <i>Journal of Theoretical Biology</i> , 2022, , 111205.	0.8	7
1487	Downsizing of COVID-19 contact tracing in highly immune populations. <i>PLoS ONE</i> , 2022, 17, e0268586.	1.1	2
1488	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
1489	Contemporary Concise Review 2021: COVID-19 and other respiratory infections. <i>Respirology</i> , 0, , .	1.3	1
1490	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
1491	COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review. <i>Vaccines</i> , 2022, 10, 948.	2.1	88
1492	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. <i>Microbial Pathogenesis</i> , 2022, 169, 105619.	1.3	4

#	ARTICLE	IF	CITATIONS
1493	Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9376-9395.	2.9	35
1494	Personality and Motivation to Comply With COVID-19 Protective Measures in Germany. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	4
1496	Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield™) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. <i>Vaccines</i> , 2022, 10, 970.	2.1	6
1498	Risky Party and Nightclub Attendance during the COVID-19 Nightlife Shutdown in New York City. <i>Journal of Urban Health</i> , 0, , .	1.8	0
1499	Types of Variants Among Increased Cases of COVID-19 in the Western Region of Saudi Arabia in June 2021. <i>Cureus</i> , 2022, , .	0.2	0
1500	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
1501	Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. <i>PLoS ONE</i> , 2022, 17, e0269917.	1.1	14
1502	Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103541.	1.4	7
1503	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
1504	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. <i>Clinical Infectious Diseases</i> , 2022, 75, S159-S166.	2.9	13
1505	Role of literacy, fear and hesitancy on acceptance of COVID-19 vaccine among village health volunteers in Thailand. <i>PLoS ONE</i> , 2022, 17, e0270023.	1.1	13
1506	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4
1507	Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. <i>International Journal of Infectious Diseases</i> , 2022, 122, 420-426.	1.5	10
1508	Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8686-8698.	2.9	63
1509	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. <i>Expert Review of Vaccines</i> , 2022, 21, 1255-1268.	2.0	30
1510	Effect of COVID-19 Delta (B.1.617.2) and Omicron (B.1.1.529) surges on emergency medicine physician compassion. <i>American Journal of Emergency Medicine</i> , 2022, , .	0.7	0
1511	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
1512	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15

#	ARTICLE	IF	CITATIONS
1513	SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes. <i>Journal of Infection and Public Health</i> , 2022, 15, 773-780.	1.9	11
1514	Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. <i>Vaccine</i> , 2022, 40, 4231-4241.	1.7	11
1515	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	3.9	6
1516	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in [®] , in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. <i>EClinicalMedicine</i> , 2022, 50, 101526.	3.2	20
1517	Associations between nighttime light and COVID-19 incidence and mortality in the United States. <i>International Journal of Applied Earth Observation and Geoinformation</i> , 2022, 112, 102855.	0.9	6
1518	Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies. <i>International Review of Neurobiology</i> , 2022, , 173-196.	0.9	5
1519	Das Immunsystem. , 2022, , 148-167.		0
1520	How has COVID-19 affected dentistry practice? The perspective of future changes in a comprehensive literature review. <i>SRM Journal of Research in Dental Sciences</i> , 2022, 13, 58.	0.1	0
1522	Commentary on "Risk of venous thromboembolism after COVID-19 vaccination". <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1562-1564.	1.9	0
1523	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
1524	Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants. <i>Radiology</i> , 2023, 306, 252-260.	3.6	33
1525	Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations. <i>PLoS Pathogens</i> , 2022, 18, e1010591.	2.1	20
1526	Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2049-2055.	0.5	7
1527	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
1528	COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021. <i>Journal of Clinical Medicine</i> , 2022, 11, 3734.	1.0	11
1529	Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1530	The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. <i>Current Issues in Molecular Biology</i> , 2022, 44, 2842-2855.	1.0	1
1531	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19

#	ARTICLE	IF	CITATIONS
1532	IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. <i>Science Immunology</i> , 2022, 7, .	5.6	8
1535	Novel Insights in Spatial Epidemiology Utilizing Explainable AI (XAI) and Remote Sensing. <i>Remote Sensing</i> , 2022, 14, 3074.	1.8	16
1536	The COVID-19 delta or detrimental variant?. <i>International Journal of Oral Health Dentistry</i> , 2022, 8, 112-115.	0.0	0
1537	Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern. <i>Nature Communications</i> , 2022, 13, .	5.8	28
1538	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6064-6073.	2.1	14
1539	COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	39
1540	Quantifying the Effects of Non-Pharmaceutical and Pharmaceutical Interventions Against Covid-19 Epidemic in the Republic of Korea: Mathematical Model-Based Approach Considering Age Groups and the Delta Variant. <i>Mathematical Modelling of Natural Phenomena</i> , 2022, 17, 39.	0.9	2
1541	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. <i>PLoS ONE</i> , 2022, 17, e0270801.	1.1	18
1542	Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study. <i>BMJ Open</i> , 2022, 12, e057281.	0.8	1
1543	Short-sighted decision-making by those not vaccinated against COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1544	Reducing barriers to accessing administrative data on SARS-CoV-2 vaccination for research. <i>Cmaj</i> , 2022, 194, E943-E947.	0.9	3
1546	The disease course of hospitalized COVID-19 patients during the delta and omicron periods in consideration of vaccination status. <i>Deutsches Arzteblatt International</i> , 0, , .	0.6	1
1547	Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	20
1548	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
1549	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9
1550	Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. <i>BMC Medicine</i> , 2022, 20, .	2.3	20
1551	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
1552	Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning. <i>Journal of Physical Chemistry B</i> , 2022, 126, 5194-5206.	1.2	4

#	ARTICLE	IF	CITATIONS
1553	Genomic diversity of SARS-CoV-2 in Pakistan during the fourth wave of pandemic. <i>Journal of Medical Virology</i> , 2022, 94, 4869-4877.	2.5	11
1554	Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy. <i>PLoS ONE</i> , 2022, 17, e0265159.	1.1	4
1555	Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose. <i>Emerging Infectious Diseases</i> , 2022, 28, 1375-1383.	2.0	17
1556	SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge â€œ Denver, Colorado, and San Diego, California, Januaryâ€œApril 2021. <i>Vaccine</i> , 2022, 40, 4845-4855.	1.7	2
1557	Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 693-702.	1.5	25
1558	Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients. <i>American Journal of Nephrology</i> , 2022, 53, 586-590.	1.4	15
1559	Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. , 2022, 1, .		7
1560	The Real-World Impact of Vaccination on COVID-19 Cases During Europeâ€™s Fourth Wave. <i>International Journal of Public Health</i> , 0, 67, .	1.0	1
1561	Genomic epidemiology of Delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand. <i>Nature Communications</i> , 2022, 13, .	5.8	17
1562	Advances in COVID-19 Vaccines and New Coronavirus Variants. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1563	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
1564	Epidemiology and Transmission Dynamics of COVID-19 in an Urban Pediatric US Population. <i>Public Health Reports</i> , 0, , 003335492211052.	1.3	0
1565	Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	35
1566	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	1.7	10
1567	Should we allocate more COVID-19 vaccine doses to non-vaccinated individuals?. <i>PLOS Global Public Health</i> , 2022, 2, e0000498.	0.5	1
1568	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
1569	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
1570	PaCAR: COVID-19 Pandemic Control Decision Making via Large-Scale Agent-Based Modeling and Deep Reinforcement Learning. <i>Medical Decision Making</i> , 2022, 42, 1064-1077.	1.2	4

#	ARTICLE	IF	CITATIONS
1571	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1873-1881.	2.0	4
1572	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
1573	Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults. <i>Nature Communications</i> , 2022, 13, .	5.8	18
1574	SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. <i>IScience</i> , 2022, 25, 104759.	1.9	11
1575	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 758-766.	1.5	15
1576	COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. <i>European Journal of Cancer</i> , 2022, 175, 1-10.	1.3	34
1577	Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1435-1443.	4.6	233
1578	COVID-19 Vaccination and the Timing of Surgery Following COVID-19 Infection. <i>Annals of Surgery</i> , 2022, 276, e265-e272.	2.1	26
1580	Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients. <i>Vaccines</i> , 2022, 10, 1125.	2.1	6
1581	A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. <i>Journal of Clinical Medicine</i> , 2022, 11, 4164.	1.0	15
1582	Modeling the Impact of Vaccination on COVID-19 and Its Delta and Omicron Variants. <i>Viruses</i> , 2022, 14, 1482.	1.5	15
1583	Household Transmission of SARS-CoV-2 in Bhutan. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	0
1584	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
1585	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1586	Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 Genomes. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 963-976.	1.2	7
1587	Long-Term Effect of the COVID-19 Pandemic on the Management of Pediatric Appendicitis. <i>Pediatric Annals</i> , 2022, 51, .	0.3	0
1588	Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. <i>IScience</i> , 2022, 25, 104745.	1.9	11
1589	Rapid Antigen Diagnostics as Frontline Testing in the COVIDâ€19 Pandemic. <i>Small Science</i> , 2022, 2, .	5.8	7

#	ARTICLE	IF	CITATIONS
1590	A critical review on diverse technologies for advanced wastewater treatment during SARS-CoV-2 pandemic: What do we know?. <i>Journal of Hazardous Materials Advances</i> , 2022, 7, 100121.	1.2	10
1591	Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814. <i>Journal of Molecular Biology</i> , 2022, 434, 167706.	2.0	10
1592	Should patients with epilepsy be vaccinated against coronavirus disease 2019? A systematic review and meta-analysis. <i>Epilepsy and Behavior</i> , 2022, 134, 108822.	0.9	9
1593	Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
1594	Families in quarantine for COVID-19 in Italy. Resilience as a buffer of parental distress and problematic children's emotions and behaviors. <i>Current Psychology</i> , 2023, 42, 20101-20113.	1.7	3
1595	Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	22
1596	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. <i>BMJ</i> , The, 0, , e071249.	3.0	31
1597	Safe reopening of university campuses is possible with COVID-19 vaccination. <i>PLoS ONE</i> , 2022, 17, e0270106.	1.1	6
1598	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. <i>Cancers</i> , 2022, 14, 3598.	1.7	7
1599	A comparison of high-throughput SARS-CoV-2 sequencing methods from nasopharyngeal samples. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1600	COVID-19 Inpatient Deaths and Brought-in-Dead Cases in Malaysia. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
1601	mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	31
1602	COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1014-1025.	1.5	3
1603	Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
1604	Procalcitonin as a Predictive Factor for the Clinical Outcome of Patients with Coronavirus Disease 2019. <i>Journal of Acute Care Surgery</i> , 2022, 12, 53-62.	0.1	0
1605	Alveolar macrophages: Achilles' heel of SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	15
1606	Effectiveness of Comirnaty® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study. <i>Vaccines</i> , 2022, 10, 1170.	2.1	2
1607	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11

#	ARTICLE	IF	CITATIONS
1608	Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. <i>JAMA Network Open</i> , 2022, 5, e2223917.	2.8	19
1609	Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination-associated myocarditis – A systematic review. <i>Rechtsmedizin</i> , 0, , .	2.6	1
1610	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
1611	SARS-CoV-2 – Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1612	Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020 – June 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	4
1613	Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan. <i>Emerging Infectious Diseases</i> , 2022, 28, 1777-1784.	2.0	7
1614	Evaluation of Intervention Policies for the COVID-19 Epidemic in the Seoul/Gyeonggi Region through a Model Simulation. <i>Yonsei Medical Journal</i> , 2022, 63, 707.	0.9	1
1615	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1616	A Framework for Infectious Disease Monitoring With Automated Contact Tracing – A Case Study of COVID-19. <i>IEEE Internet of Things Journal</i> , 2023, 10, 144-165.	5.5	5
1617	Path to normality: Assessing the level of social-distancing measures relaxation against antibody-resistant SARS-CoV-2 variants in a partially-vaccinated population. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4052-4059.	1.9	5
1618	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. <i>International Journal of Biological Sciences</i> , 2022, 18, 4642-4647.	2.6	4
1619	Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model. <i>Vacunas (English Edition)</i> , 2022, 23, 144-146.	0.3	0
1621	SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	17
1622	Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. <i>PLoS ONE</i> , 2022, 17, e0271446.	1.1	2
1624	Ranking the effectiveness of non-pharmaceutical interventions to counter COVID-19 in UK universities with vaccinated population. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1625	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
1626	Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
1627	An epidemic model for SARS-CoV-2 with self-adaptive containment measures. <i>PLoS ONE</i> , 2022, 17, e0272009.	1.1	2

#	ARTICLE	IF	CITATIONS
1628	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. <i>Virus Evolution</i> , 2022, 8, .	2.2	10
1629	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
1630	Epitope-Evaluator: An interactive web application to study predicted T-cell epitopes. <i>PLoS ONE</i> , 2022, 17, e0273577.	1.1	3
1631	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	70
1632	Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers. <i>Journal of Medical Virology</i> , 2022, 94, 5867-5876.	2.5	17
1633	The SARS-CoV-2 Variants and their Impacts. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 1409-1424.	0.3	3
1634	COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, .	2.8	36
1635	Unified Therapeutic-Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	17
1636	Holistic Interpretation of Public Scenes Using Computer Vision and Temporal Graphs to Identify Social Distancing Violations. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 8428.	1.3	1
1637	Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. <i>Nature Communications</i> , 2022, 13, .	5.8	62
1638	Genomic epidemiology of the first two waves of SARS-CoV-2 in Canada. <i>ELife</i> , 0, 11, .	2.8	21
1639	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1641	Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response. <i>Vaccines</i> , 2022, 10, 1281.	2.1	11
1642	Transcriptome Analysis of Peripheral Blood Mononuclear Cells Response in Patients with Severe COVID-19 Reveals Crucial Genes Regulating Protein Ubiquitination. <i>Medical Science Monitor</i> , 0, 28, .	0.5	5
1643	COVID-19 Hospitalization Among Children <18 Years by Variant Wave in Norway. <i>Pediatrics</i> , 2022, 150, .	1.0	23
1644	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1645	Group-based trajectory modeling to identify health beliefs of COVID-19 vaccination and its predictors: A cohort study in China. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
1646	Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
1647	Non-pharmacological interventions of travel restrictions and cancelation of public events had a major reductive mortality affect during pre-vaccination coronavirus disease 2019 period. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1648	Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2022, 380, .	1.6	7
1649	Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	11
1650	Differential Infectivity of Original and Delta Variants of SARS-CoV-2 in Children Compared to Adults. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
1651	Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021. <i>Medicine (United States)</i> , 2022, 101, e30019.	0.4	3
1652	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. <i>Nature Communications</i> , 2022, 13, .	5.8	33
1653	Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study. <i>Biomedicine</i> , 2022, 10, 2063.	1.4	2
1654	Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1750-1756.	0.5	23
1655	Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021â€“2022: A Naturalistic Case-Control Study in Sweden. <i>Vaccines</i> , 2022, 10, 1273.	2.1	1
1656	COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e061126.	0.8	7
1657	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. <i>Human Immunology</i> , 2022, 83, 755-767.	1.2	10
1658	SARS-CoV-2 Vaccination Coverage and Factors Associated with Low Uptake in a Cohort of People Living with HIV. <i>Microorganisms</i> , 2022, 10, 1666.	1.6	6
1659	Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1661	Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, .	1.6	15
1663	Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	4
1664	Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	7
1665	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
1666	COVID-19 Vaccination and Medical Liability: An International Perspective in 18 Countries. <i>Vaccines</i> , 2022, 10, 1275.	2.1	13

#	ARTICLE	IF	CITATIONS
1667	Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2) Tj ETQq0 0 0 2gBT /Over10 Tf e108-e115.	0.1	1
1668	Breakthrough COVID-19 infection according to the infectious diseases hospital. Kazan Medical Journal, 2022, 103, 541-551.	0.1	1
1670	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. Scientific Reports, 2022, 12, .	1.6	26
1671	Parental perceptions and the 5C psychological antecedents of COVID-19 vaccination during the first month of omicron variant surge: A large-scale cross-sectional survey in Saudi Arabia. Frontiers in Pediatrics, 0, 10, .	0.9	4
1673	COVID-19 forecasting using new viral variants and vaccination effectiveness models. Computers in Biology and Medicine, 2022, 149, 105986.	3.9	14
1674	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
1675	Inactivated vaccine injection and immunoglobulin G levels related to severe coronavirus disease 2019 (Delta) pneumonia in Xi'an, China: A single-centered, retrospective, observational study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2
1676	Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan. Scientific Reports, 2022, 12, .	1.6	10
1677	Characteristics and Vaccines: Five Variants of Concern of SARS-CoV-2. , 0, 8, 630-634.		0
1678	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
1679	Correspondence to "Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA EAACI GA2LEN consensus" Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2571-2573.	2.7	4
1680	Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study. Vaccine, 2022, 40, 5675-5682.	1.7	2
1682	Rapid Rollout and Initial Uptake of a Booster COVID-19 Vaccine Among Israel Defense Forces Soldiers. , 0, , .		3
1684	Emerging trends of research on mRNA vaccines: A co-citation analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
1685	Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Vaccine, 2022, 40, 5322-5332.	1.7	9
1686	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. Nature Communications, 2022, 13, .	5.8	23
1687	Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins. International Journal of Molecular Sciences, 2022, 23, 8680.	1.8	7
1688	Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health, 2022, 22, .	1.2	15

#	ARTICLE	IF	CITATIONS
1689	Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape. <i>Folia Microbiologica</i> , 2023, 68, 17-28.	1.1	16
1690	Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 38-49.	2.5	12
1691	Initial introduction and spread of the SARS-CoV-2 AY.4.2.1 Delta variant in Bulgaria, a genomic insight. <i>Journal of Medical Virology</i> , 0, , .	2.5	2
1692	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. <i>EBioMedicine</i> , 2022, 83, 104196.	2.7	26
1693	Malaysian public preferences and decision making for COVID-19 vaccination: A discrete choice experiment. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 27, 100534.	1.3	5
1694	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
1695	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
1696	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
1697	Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 28, 100571.	1.3	12
1698	Large interfacial relocation in RBD-ACE2 complex may explain fast-spreading property of Omicron. <i>Journal of Molecular Structure</i> , 2022, 1270, 133842.	1.8	0
1699	Influence of Media Framing on Cognition of COVID-19 Vaccine Effectiveness: The Mediating Role of Emotions. <i>American Journal of Health Behavior</i> , 2022, 46, 423-441.	0.6	0
1700	Outbreak of SARS-CoV-2 B.1.617.2 (Delta Variant) in a Youth Camp Associated With Community Spread, Nebraska, June–July 2021. <i>Public Health Reports</i> , 2023, 138, 157-163.	1.3	1
1701	COVID-19 Vaccination Concerns and Reasons for Acceptance Among US Health Care Personnel. <i>Public Health Reports</i> , 0, , 003335492211205.	1.3	1
1702	Prediction of COVID-19 infection spread through agent-based simulation. , 2022, , .		1
1703	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
1704	Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. <i>Respiratory Medicine</i> , 2022, 202, 106986.	1.3	6
1705	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
1706	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 1999-2008.	2.0	12

#	ARTICLE	IF	CITATIONS
1707	The heterogeneous mixing model of COVID-19 with interventions. <i>Journal of Theoretical Biology</i> , 2022, 553, 111258.	0.8	6
1709	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
1710	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
1711	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
1712	Immune system diversity against SARS-CoV-2 infection and vaccines. , 2022, 1, 153.		0
1713	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
1714	Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	7
1715	COVID-19 breakthrough infections amongst ChAdOx1 nCoV-19 (Covishield) vaccinated health-care workers and its clinical manifestations: A prospective observational study. <i>Journal of Marine Medical Society</i> , 2022, 24, 154.	0.0	0
1716	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1717	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq1 1 0.784314 rgBT ₂ /Overload	0.4	0
1718	COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine Dose. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
1719	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
1720	A Networked Competitive Multi-Virus SIR Model: Analysis and Observability. <i>IFAC-PapersOnLine</i> , 2022, 55, 13-18.	0.5	0
1721	Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1722	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
1723	Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. <i>Journal of Occupational and Environmental Medicine</i> , 2022, 64, 788-796.	0.9	0
1724	SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games. <i>Internal Medicine</i> , 2022, 61, 3659-3666.	0.3	2
1725	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. <i>Health Evaluation and Promotion</i> , 2022, 49, 462-469.	0.0	0

#	ARTICLE	IF	CITATIONS
1726	Knowledge mapping analysis of mental health research on COVID-19. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
1727	Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 137-153.	0.4	2
1728	Sports Participation and Anti-Epidemic: Empirical Evidence on the Influence of Regular Physical Activity on the COVID-19 Pandemic in Mainland China. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10689.	1.2	1
1729	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. <i>Life</i> , 2022, 12, 1318.	1.1	3
1730	The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City. <i>Acute and Critical Care</i> , 2022, 37, 339-346.	0.6	4
1731	Faciliter lâ€™accÃ©s aux donnÃ©es administratives sur la vaccination anti-SRAS-CoV-2 aux fins de la recherche. <i>Cmaj</i> , 2022, 194, E1147-E1152.	0.9	0
1732	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
1733	Vaccination and Mortality of Patients with a Novel Coronavirus Infection (COVID-19): A Global Approach. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2022, 32, 23-28.	0.2	0
1734	Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study. <i>Vacunas</i> , 2023, 24, 27-36.	1.1	10
1735	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spikeâ€™ACE2 Proteinâ€™Protein Interaction from a Chemical Space of Privileged Protein Binders. <i>Pharmaceuticals</i> , 2022, 15, 1084.	1.7	5
1736	Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. <i>Nature Communications</i> , 2022, 13, .	5.8	89
1737	Antibody response and intraâ€™host viral evolution after plasma therapy in <scp>COVID</scp>â€™19 patients preâ€™exposed or not to Bâ€™cellâ€™depleting agents. <i>British Journal of Haematology</i> , 2022, 199, 549-559.	1.2	9
1738	COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged â€™65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021. <i>PLoS ONE</i> , 2022, 17, e0274008.	1.1	9
1739	Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
1741	Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial). <i>International Journal of Infectious Diseases</i> , 2022, 124, 190-198.	1.5	4
1742	Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness. <i>Archives of Virology</i> , 2022, 167, 2677-2688.	0.9	3
1743	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. <i>PLoS Pathogens</i> , 2022, 18, e1010802.	2.1	27
1744	Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021. <i>Journal of Medical Economics</i> , 2022, 25, 1039-1050.	1.0	1

#	ARTICLE	IF	CITATIONS
1745	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1746	Consumer acceptance of autonomous delivery robots for last-mile delivery: Technological and health perspectives. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	8
1747	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. <i>Vaccine</i> , 2022, , .	1.7	3
1748	Need for focused pharmacovigilance in the face of rapid COVID-19 vaccine development. <i>Current Drug Safety</i> , 2022, 17, .	0.3	0
1749	Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
1750	Tracing the trajectories of SARS-CoV-2 variants of concern between December 2020 and September 2021 in the Canary Islands (Spain). <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
1751	Temporal Trend of COVID-19 Vaccine Acceptance and Factors Influencing International Travellers. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 223.	0.9	3
1752	Global Implications for COVID-19 Vaccine Series Completion: Insights from Real-World Data from the United States. <i>Vaccines</i> , 2022, 10, 1561.	2.1	0
1753	Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study. <i>Hepatology</i> , 2023, 77, 834-850.	3.6	7
1754	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
1755	The economic impact of COVID-19 interventions: A mathematical modeling approach. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
1756	GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2â€R671 diâ€methylation. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	9
1757	Bioinformatics-based SARS-CoV-2 epitopes design and the impact of Spike protein mutants on epitope humoral immunities. <i>Immunobiology</i> , 2022, , 152287.	0.8	2
1758	Computed Tomographic Imaging Features of COVID-19 Pneumonia Caused by the Delta (B.1.617.2) and Omicron (B.1.1.529) Variant in a German Nested Cohort Pilot Study Group. <i>Tomography</i> , 2022, 8, 2435-2449.	0.8	12
1759	Estimating Waning of Vaccine Effectiveness: a Simulation Study. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	2
1760	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
1761	Features of the spread of a new coronavirus infection in the territory of municipalities of the Rostov region. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2022, 99, 410-419.	0.3	2
1762	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55

#	ARTICLE	IF	CITATIONS
1763	Optimizing global COVID-19 vaccine allocation: An agent-based computational model of 148 countries. <i>PLoS Computational Biology</i> , 2022, 18, e1010463.	1.5	8
1764	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1
1765	Target-Specific Machine Learning Scoring Function Improved Structure-Based Virtual Screening Performance for SARS-CoV-2 Drugs Development. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11003.	1.8	11
1766	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
1767	Psychosocial Determinants of Hand Hygiene, Facemask Wearing, and Physical Distancing During the COVID-19 Pandemic: A Systematic Review and Meta-analysis. <i>Annals of Behavioral Medicine</i> , 2022, 56, 1174-1187.	1.7	11
1768	A Lesson from the Green Pass Experience in Italy: A Narrative Review. <i>Vaccines</i> , 2022, 10, 1483.	2.1	8
1769	Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine. <i>Viruses</i> , 2022, 14, 2023.	1.5	8
1770	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
1771	Current clinical status of new COVID-19 vaccines and immunotherapy. <i>Environmental Science and Pollution Research</i> , 0, , .	2.7	5
1772	COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia. <i>BMC Public Health</i> , 2022, 22, .	1.2	4
1773	Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003992.	3.9	83
1774	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	2.1	1
1775	Challenges of vaccination and herd immunity in COVID-19 and management strategies. <i>Clinical Respiratory Journal</i> , 2022, 16, 708-716.	0.6	12
1776	Access to Health Care Improves COVID-19 Vaccination and Mitigates Health Disparities Among Medicare Beneficiaries. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 1569-1575.	1.8	2
1777	Vaccine Effectiveness against SARS-CoV-2 Variants in Adolescents from 15 to 90 Days after Second Dose: A Population-Based Test-Negative Case-Control Study. <i>Journal of Pediatrics</i> , 2023, 253, 189-196.e2.	0.9	5
1779	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. <i>Npj Vaccines</i> , 2022, 7, .	2.9	3
1780	A Bioinformatics Tool for Predicting Future COVID-19 Waves Based on a Retrospective Analysis of the Second Wave in India: Model Development Study. <i>JMIR Bioinformatics and Biotechnology</i> , 2022, 3, e36860.	0.4	4
1781	Advancements in COVID-19 Testing: An in-depth overview. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	0

#	ARTICLE	IF	CITATIONS
1782	Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11
1783	Changes of factors associated with vaccine hesitancy in Chinese residents: A qualitative study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1784	Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months—A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 11422.	1.2	1
1785	Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
1786	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. <i>Viruses</i> , 2022, 14, 1966.	1.5	6
1787	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10374.	1.8	10
1789	Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	22
1790	Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. <i>Clinical Microbiology and Infection</i> , 2023, 29, 215-220.	2.8	25
1791	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
1792	Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7
1793	SARS-CoV-2 Variants Infection in Relationship to Imaging-based Pneumonia and Clinical Outcomes. <i>Radiology</i> , 2023, 306, .	3.6	19
1794	Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1596.	2.1	1
1795	SARS-CoV-2 Mutations Responsible for Immune Evasion Leading to Breakthrough Infection. <i>Cureus</i> , 2022, , .	0.2	0
1796	Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. <i>Applied Mathematical Modelling</i> , 2023, 114, 447-465.	2.2	23
1797	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
1800	A comparative overview of SARS-CoV-2 and its variants of concern. <i>Infezioni in Medicina</i> , 2022, 30, .	0.7	6
1801	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
1802	Insight into Delta variant dominated second wave of COVID-19 in Nepal. <i>Epidemics</i> , 2022, 41, 100642.	1.5	7

#	ARTICLE	IF	CITATIONS
1803	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	2.8	8
1804	Peripartum Outcomes Associated With COVID-19 Vaccination During Pregnancy. <i>JAMA Pediatrics</i> , 2022, 176, 1098.	3.3	33
1805	Lessons from the pandemic: Responding to emerging zoonotic viral diseasesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1518, 209-225.	1.8	4
1806	Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study. <i>Korean Journal of Pain</i> , 2022, 35, 458-467.	0.8	3
1807	Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19â€”Related Acute Respiratory Distress Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2235219.	2.8	18
1809	Global stability and optimal control for a COVID-19 model with vaccination and isolation delays. <i>Results in Physics</i> , 2022, 42, 106011.	2.0	10
1810	Mathematical modeling to study the interactions of two risk populations in COVID-19 spread in Thailand. <i>AIMS Mathematics</i> , 2022, 8, 2044-2061.	0.7	1
1811	Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging. <i>Theranostics</i> , 2022, 12, 7509-7531.	4.6	43
1812	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
1813	Inequities in the deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region, 2020â€”2021. <i>BMJ Global Health</i> , 2022, 7, e008139.	2.0	5
1814	Importancia de la vigilancia genÃ©mica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1815	Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	0
1816	Protection against Omicron from Vaccination and Previous Infection in a Prison System. <i>New England Journal of Medicine</i> , 2022, 387, 1770-1782.	13.9	40
1817	Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1818	Does Prophylactic Oral Zinc Reduce the Risk of Contracting COVID-19?. <i>Cureus</i> , 2022, , .	0.2	0
1819	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. <i>Nature Medicine</i> , 2023, 29, 147-157.	15.2	32
1820	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1821	Deciphering the Mechanism of YuPingFeng Granules in Treating Pneumonia: A Network Pharmacology and Molecular Docking Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	1

#	ARTICLE	IF	CITATIONS
1822	Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network. <i>Diagnostics</i> , 2022, 12, 2539.	1.3	9
1823	The Relationship between Mustard Import and COVID-19 Deaths: A Workflow with Cross-Country Text Mining. <i>Healthcare (Switzerland)</i> , 2022, 10, 2071.	1.0	0
1824	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
1825	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
1826	Comparison of Clinical Course of Covid 19 Infections in Vaccinated and Unvaccinated Individuals. <i>International Journal of Pharmaceutical Sciences Review and Research</i> , 0, , 61-65.	0.1	0
1827	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
1828	Prevalence and Factors Associated with Caregiversâ€™ Hesitancy in Immunizing Dependent Older Adults with COVID-19 Vaccines: A Cross-Sectional Survey. <i>Vaccines</i> , 2022, 10, 1748.	2.1	1
1832	Five waves of the COVID-19 pandemic and greenâ€“blue spaces in urban and rural areas in Poland. <i>Environmental Research</i> , 2023, 216, 114662.	3.7	8
1833	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
1834	Characteristics of hospitalized patients with SARS-CoV-2 infection during successive waves of the COVID-19 pandemic in a reference hospital in Spain. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1835	Gramâ€“scale mRNA Production Using a 250â€“mL Singleâ€“Use Bioreactor. <i>Chemie-Ingenieur-Technik</i> , 2022, 94, 1928-1935.	0.4	11
1836	Psychological research of the children with chronic kidney disease and their guardians during the COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1837	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1838	Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study. <i>Viruses</i> , 2022, 14, 2416.	1.5	3
1839	Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. <i>ACS Nano</i> , 2022, 16, 16757-16775.	7.3	11
1840	Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort. <i>Emerging Microbes and Infections</i> , 2022, 11, 2636-2644.	3.0	9
1841	Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. <i>MBio</i> , 0, , .	1.8	3
1843	Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach. <i>Life</i> , 2022, 12, 1715.	1.1	2

#	ARTICLE	IF	CITATIONS
1844	Demographics and Clinical Characteristics of COVID-19-vaccinated Patients Admitted to ICU: A Multicenter Cohort Study from India (PostCoVac Study-COVID Group). <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1184-1191.	0.3	4
1845	Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccination. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1846	Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 398-407.	2.9	24
1847	Modified susceptibleâ€“exposedâ€“infectiousâ€“recovered model for assessing the effectiveness of non-pharmaceutical interventions during the COVID-19 pandemic in Seoul. <i>Journal of Theoretical Biology</i> , 2023, 557, 111329.	0.8	4
1849	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARSâ€“CoVâ€“2. <i>Advanced Science</i> , 2022, 9, .	5.6	17
1850	Infection of the oral cavity with SARS-CoV-2 variants: Scope of salivary diagnostics. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
1851	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1852	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
1853	Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary childrenâ€™s medical center in Shanghai, China. <i>World Journal of Pediatrics</i> , 2023, 19, 87-95.	0.8	7
1854	Case Report of Multisystem Inflammatory Syndrome in Adults (MIS-A): A 31-Year-Old Man with Fever, Rash, and Cardiac Symptoms 6 Weeks Following SARS-CoV-2 Infection, Successfully Resuscitated Following Cardiac Arrest. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
1855	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0
1856	Association between Brain Injury Markers and Testosterone in Critically-Ill COVID-19 Male Patients. <i>Microorganisms</i> , 2022, 10, 2095.	1.6	5
1857	Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. <i>PLoS ONE</i> , 2022, 17, e0272594.	1.1	1
1858	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. <i>Npj Vaccines</i> , 2022, 7, .	2.9	24
1859	Changes in the types of patients in burn unit: A single center experience. <i>Burns Open</i> , 2022, 6, 200-207.	0.2	1
1860	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
1861	Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). <i>Biosensors</i> , 2022, 12, 950.	2.3	2
1862	Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Caseâ€“Control Study. <i>Vaccines</i> , 2022, 10, 1855.	2.1	0

#	ARTICLE	IF	CITATIONS
1863	Potent and biostable inhibitors of the main protease of SARS-CoV-2. <i>IScience</i> , 2022, 25, 105365.	1.9	9
1864	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5
1865	Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1866	COVID-DSNet: A novel deep convolutional neural network for detection of coronavirus (SARS-CoV-2) cases from CT and Chest X-Ray images. <i>Artificial Intelligence in Medicine</i> , 2022, 134, 102427.	3.8	16
1868	Impact of perceptions and attitudes on air travel choices in the post-COVID-19 era: A cross-national analysis of stated preference data. <i>Travel Behaviour & Society</i> , 2023, 30, 220-239.	2.4	0
1869	A layman approach to adopt COVID-19 appropriate behaviour and vaccination: A narrative review. <i>Asian Journal of Pharmaceutical Research and Health Care</i> , 2022, 14, 1.	0.0	0
1870	Vaccination and COVID-19 infection among adults aged 45 years and above in a North-Eastern state of India. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6375.	0.3	0
1871	Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study. , 2023, 8, 100106.		4
1872	Experiencing herd immunity in virtual reality increases COVID-19 vaccination intention: Evidence from a large-scale field intervention study. <i>Computers in Human Behavior</i> , 2023, 139, 107533.	5.1	8
1873	COVID-19, are We There Yet?. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2345-2347.	0.0	0
1874	Dual Inhibitors of Main Protease (M ^{Pro}) and Cathepsin L as Potent Antivirals against SARS-CoV2. <i>Journal of the American Chemical Society</i> , 2022, 144, 21035-21045.	6.6	20
1875	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	5
1877	Changes in preventive behaviour after COVID-19 vaccination in Thailand: a cross-sectional study. <i>BMC Public Health</i> , 2022, 22, .	1.2	6
1878	Effectiveness of SARS-CoV-2 inactivated vaccine and the correlation to neutralizing antibodies: A test-negative case-control study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1879	A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	5
1880	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. <i>Biomedicines</i> , 2022, 10, 2892.	1.4	4
1881	Reactogenicity of COVID-19 Vaccines in Patients With a History of COVID-19 Infection: A Survey Conducted in Pakistan. <i>Cureus</i> , 2022, , .	0.2	0
1882	COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6

#	ARTICLE	IF	CITATIONS
1883	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1884	A 12-month projection to September 2022 of the COVID-19 epidemic in the UK using a dynamic causal model. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1885	Immunosuppressant and SARS-CoV-2 Vaccine Antibody Response After Lung Transplantation. <i>Transplantation Proceedings</i> , 2022, 54, 2692-2697.	0.3	1
1886	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. <i>Expert Review of Vaccines</i> , 2022, 21, 1739-1761.	2.0	2
1887	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
1888	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	2
1889	Preventive Behaviors and Information Sources during COVID-19 Pandemic: A Cross-Sectional Study in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14511.	1.2	8
1890	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. <i>Vaccines</i> , 2022, 10, 1926.	2.1	29
1892	A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort. <i>BMC Immunology</i> , 2022, 23, .	0.9	4
1893	Assessment of COVID-19 Anxiety Levels and Attitudes to COVID-19 Vaccine among Older Adults in Poland: A Pilot Study. <i>Vaccines</i> , 2022, 10, 1918.	2.1	1
1894	Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	0
1896	Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1897	COVID-19 deaths in children and young people in England, March 2020 to December 2021: An active prospective national surveillance study. <i>PLoS Medicine</i> , 2022, 19, e1004118.	3.9	16
1898	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
1899	Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
1901	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	1.6	10
1902	Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. <i>Viruses</i> , 2022, 14, 2541.	1.5	6
1903	Effect of vaccination against Covid-19 one year after its introduction in Brazil. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2022, 8, .	0.9	3

#	ARTICLE	IF	CITATIONS
1905	Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis. <i>Transplantation</i> , 2023, 107, 204-215.	0.5	10
1906	Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
1907	The Vaccine World of COVID-19: India's Contribution. <i>Vaccines</i> , 2022, 10, 1943.	2.1	7
1908	Different Interventions for COVID-19 Primary and Booster Vaccination? Effects of Psychological Factors and Health Policies on Vaccine Uptake. <i>Medical Decision Making</i> , 2023, 43, 239-251.	1.2	8
1909	The importance of sustained compliance with physical distancing during COVID-19 vaccination rollout. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
1910	The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.2	17
1911	Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: a multi-model study. <i>The Lancet Regional Health Americas</i> , 2023, 17, 100398.	1.5	7
1912	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. <i>Journal of Theoretical Biology</i> , 2023, 559, 111384.	0.8	7
1913	COVID-19 endgame: From pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. <i>Journal of Theoretical Biology</i> , 2023, 559, 111368.	0.8	29
1914	Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 227, 896-902.	3.6	2
1915	Smartphone-controlled biosensor for viral respiratory infectious diseases: Screening and response. <i>Talanta</i> , 2023, 254, 124167.	2.9	2
1916	Strategies for the Emergency Treatment of Pregnant Women with Neurological Symptoms during the COVID-19 Pandemic. , 2022, .		0
1917	Variante Delta del SARS-CoV-2 en Bogotá, Colombia. , 2022, 18, 15-16.		0
1918	Heterologous vaccination of BNT162b2 in Ad26. COV2.S-vaccinated healthcare workers elicits long-term humoral immune response. <i>South African Medical Journal</i> , 2022, 112, 827-838.	0.2	0
1919	Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?. <i>Vacunas (English Edition)</i> , 2022, 23, S121-S122.	0.3	0
1920	Optimization of Vaccination Clinics to Improve Staffing Decisions for COVID-19: A Time-Motion Study. <i>Vaccines</i> , 2022, 10, 2045.	2.1	0
1922	Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	9
1923	Structural evolution of Delta lineage of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 1116-1140.	3.6	5

#	ARTICLE	IF	CITATIONS
1924	COVID-19 vaccines: a geographic, social and policy view of vaccination efforts in Ontario, Canada. Cambridge Journal of Regions, Economy and Society, 2022, 15, 757-770.	1.7	4
1926	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. Frontiers in Immunology, 0, 13, .	2.2	14
1927	Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS-CoV-2 Delta variant: A comprehensive review. Reviews in Medical Virology, 0, , .	3.9	0
1928	Discovering new potential inhibitors to SARS-CoV-2 RNA dependent RNA polymerase (RdRp) using high throughput virtual screening and molecular dynamics simulations. Scientific Reports, 2022, 12, .	1.6	7
1929	Optimizing national border reopening policies in the COVID-19 pandemic: A modeling study. Frontiers in Public Health, 0, 10, .	1.3	0
1930	A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior. Scientific Reports, 2022, 12, .	1.6	5
1931	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Frontiers in Microbiology, 0, 13, .	1.5	5
1932	Modeling COVID-19 transmission between age groups in the United States considering virus mutations, vaccinations, and reinfection. Scientific Reports, 2022, 12, .	1.6	1
1933	Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality. Scientific Reports, 2022, 12, .	1.6	5
1934	Perspectives on the COVID-19 vaccine uptake: a qualitative study of community members and health workers in Zambia. BMJ Open, 2022, 12, e058028.	0.8	4
1935	A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science, 2022, 378, 899-904.	6.0	92
1936	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2
1937	Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529). BMC Medicine, 2022, 20, .	2.3	13
1938	Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing. Scientific Reports, 2022, 12, .	1.6	3
1939	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. Journal of Infectious Diseases, 0, , .	1.9	2
1940	Contested bodies and delayed decisions: Attitudes to COVID-19 vaccines among Jamaicans. Opera, 2022, , 185-207.	0.2	0
1941	Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants. Virology Journal, 2022, 19, .	1.4	3
1942	Navigating COVID-19 and related challenges to completing clinical trials: Lessons from the PATRIOT and STEP-UP randomized prevention trials. Clinical Trials, 0, , 174077452211400.	0.7	0

#	ARTICLE	IF	CITATIONS
1943	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
1944	COVID-19 vaccine hesitancy among Italian people with multiple sclerosis. <i>Neurological Sciences</i> , 2023, 44, 803-808.	0.9	1
1945	Coupling the Within-Host Process and Between-Host Transmission of COVID-19 Suggests Vaccination and School Closures are Critical. <i>Bulletin of Mathematical Biology</i> , 2023, 85, .	0.9	3
1946	SARS-CoV-2 viral load and shedding kinetics. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	57
1947	International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2022, 23, e544-e551.	5.1	6
1948	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299.	0.2	0
1952	Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation. <i>Vaccines</i> , 2022, 10, 2069.	2.1	2
1953	SARS-CoV-2 infection among healthcare workers whom already received booster vaccination during epidemic outbreak of omicron variant in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	4
1954	Increasing yield of in vitro transcription reaction with at-line high pressure liquid chromatography monitoring. <i>Biotechnology and Bioengineering</i> , 2023, 120, 737-747.	1.7	14
1955	Knowledge, Attitude, and Acceptance of Sinopharm and AstraZeneca's COVID-19 Vaccines among Egyptian Population: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16803.	1.2	2
1956	Using a real-world network to model the trade-off between stay-at-home restriction, vaccination, social distancing and working hours on COVID-19 dynamics. <i>PeerJ</i> , 0, 10, e14353.	0.9	1
1957	Tiered social distancing policies and epidemic control. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2022, 478, .	1.0	1
1958	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
1959	Epidemiological characteristics and quarantine assessment of imported international COVID-19 cases, March to December 2020, Chengdu, China. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1961	A locational analytics approach to COVID-19 discrimination and inequality against minorities across the United States. <i>Social Science and Medicine</i> , 2023, 318, 115618.	1.8	1
1962	Case series in Indonesia: B.1.617.2 (delta) variant of SARS-CoV-2 infection after a second dose of vaccine. <i>World Journal of Clinical Cases</i> , 0, 10, 13216-13226.	0.3	1
1963	CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	11
1964	Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. <i>Nature Communications</i> , 2022, 13, .	5.8	18

#	ARTICLE	IF	CITATIONS
1965	Vaccinated Healthcare Workersâ€™ Adherence to COVID-19 Prevention Measures and Associated Factors in Northwest Ethiopia: A Facility-Based Cross-Sectional Study. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 2389-2398.	1.2	0
1966	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2022, , .	0.3	3
1967	Comparative analysis of risk factors for COVID-19 mortality before, during and after the vaccination programme in Mexico. <i>Public Health</i> , 2023, 215, 94-99.	1.4	0
1969	Data-driven scenario-based model projections and management of the May 2021 COVID-19 resurgence in India. <i>PLOS Global Public Health</i> , 2022, 2, e0001382.	0.5	0
1970	COVID-19 Vaccines, Effectiveness, and Immune Responses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15415.	1.8	9
1972	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 212-222.	1.5	9
1973	Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study. <i>Vaccines</i> , 2023, 11, 25.	2.1	3
1975	Vaccine stockpile sharing for selfish objectives. <i>PLOS Global Public Health</i> , 2022, 2, e0001312.	0.5	0
1976	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. <i>Vaccines</i> , 2022, 10, 2111.	2.1	1
1977	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome. <i>Clinical Infectious Diseases</i> , 2023, 76, 1539-1549.	2.9	16
1979	Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies. <i>PLoS ONE</i> , 2022, 17, e0278624.	1.1	3
1980	Age-Related Model for Estimating the Symptomatic and Asymptomatic Transmissibility of COVID-19 Patients. <i>Biometrics</i> , 2023, 79, 2525-2536.	0.8	1
1981	Efficacy and safety profile of corticosteroids and non-steroidal anti-inflammatory drugs in COVID-19 management: A narrative review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
1982	Development of therapeutic vaccines for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	11
1983	A genetically engineered, stem-cell-derived cellular vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100843.	3.3	0
1984	Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19â€™ Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults â€™ VISION Network, Nine States, Septemberâ€™November 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 1616-1624.	9.0	65
1985	Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. <i>Vaccines</i> , 2022, 10, 2132.	2.1	6
1986	Nanosopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM. <i>Nano Letters</i> , 2023, 23, 619-628.	4.5	4

#	ARTICLE	IF	CITATIONS
1987	Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, January–June 2021. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
1988	COVID-19 Ramifications: A Scientific Approach to Bridge the Existing Gap between COVID Vaccines Hesitancy and Effectiveness. <i>Avicenna Journal of Medicine</i> , 0, , .	0.3	0
1989	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. <i>Molecules</i> , 2023, 28, 795.	1.7	8
1990	The benefits and costs of U.S. employer COVID-19 vaccine mandates. <i>Risk Analysis</i> , 2023, 43, 2053-2068.	1.5	1
1991	Lessons from COVID-19 for improving diagnostic access in future pandemics. <i>Lab on A Chip</i> , 2023, 23, 1376-1388.	3.1	3
1992	Death from COVID-19 in a Fully Vaccinated Subject: A Complete Autopsy Report. <i>Vaccines</i> , 2023, 11, 142.	2.1	3
1996	Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England. <i>Emerging Infectious Diseases</i> , 2023, 29, 127-132.	2.0	5
1997	Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2023, 259, 263-271.	0.5	3
1998	Flight Training Subject Identification Method Based on Multivariate Subsequence Search With Double Windows. <i>IEEE Access</i> , 2023, 11, 3221-3231.	2.6	1
2000	RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq. <i>Cell Chemical Biology</i> , 2023, 30, 85-96.e6.	2.5	3
2001	COVID-19 Health Passes: Practical and Ethical Issues. <i>Journal of Bioethical Inquiry</i> , 2023, 20, 125-138.	0.9	3
2002	COVID-19 infection rates and mitigation strategies in orthodontic practices. <i>BMC Oral Health</i> , 2023, 23, .	0.8	2
2003	High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2. <i>SLAS Discovery</i> , 2023, 28, 95-101.	1.4	3
2004	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.	1.9	1
2005	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
2006	Antibody responses elicited by mRNA vaccination in firefighters persist six months and correlate inversely with age and directly with BMI. <i>Heliyon</i> , 2023, 9, e12746.	1.4	1
2007	The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	12
2008	COVID-19 vaccination status and its effect on outcome and disease severity. <i>International Journal of Community Medicine and Public Health</i> , 2023, 10, 629-634.	0.0	1

#	ARTICLE	IF	CITATIONS
2009	Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials. <i>Cureus</i> , 2023, , .	0.2	1
2010	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
2011	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. <i>Journal of Infection and Public Health</i> , 2023, 16, 233-249.	1.9	7
2012	Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana. <i>Emerging Infectious Diseases</i> , 2023, 29, 360-370.	2.0	2
2013	Reasons for COVID-19 vaccine hesitancy in ethnic minority groups: A systematic review and thematic synthesis of initial attitudes in qualitative research. <i>SSM Qualitative Research in Health</i> , 2023, 3, 100210.	0.6	13
2014	Safeguarding Against the Analog of Antimicrobial-Resistance Development. , 2023, , 163-176.		0
2015	A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases. <i>British Journal of Dermatology</i> , 2023, 188, 268-277.	1.4	4
2017	Assessing the Dynamics of COVID-19 Morbidity and Mortality in Response to Mass Vaccination: A Comparative Study Between Saudi Arabia and the United Kingdom. <i>Cureus</i> , 2022, , .	0.2	3
2018	Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. <i>Journal of Immunology</i> , 2022, 209, 2104-2113.	0.4	8
2019	Biology of the SARS-CoV-2 Coronavirus. <i>Biochemistry (Moscow)</i> , 2022, 87, 1662-1678.	0.7	2
2021	The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7811-7821.	1.1	2
2022	One Year of COVID-19 Vaccine Misinformation on Twitter: Longitudinal Study. <i>Journal of Medical Internet Research</i> , 0, 25, e42227.	2.1	13
2024	Comparison of biomarkers of COVID-19 patients with the alpha variant (B.1.1.7), the delta variant (B.1.617), and no mutation detected. <i>The European Research Journal</i> , 0, , 1-9.	0.1	0
2026	Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years. <i>JAMA Pediatrics</i> , 2023, 177, 384.	3.3	27
2027	Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness. <i>Clinical Infectious Diseases</i> , 2023, 76, 1615-1625.	2.9	4
2028	Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	7
2029	Loss-framing of information and pre-vaccination consultation improve COVID-19 vaccine acceptance: A survey experiment. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
2030	Mental Health Problems During COVID-19 and Attitudes Toward Digital Therapeutics. <i>Psychiatry Investigation</i> , 2023, 20, 52-61.	0.7	3

#	ARTICLE	IF	CITATIONS
2031	Bivalent Omicron BA.1â€“Adapted BNT162b2 Booster in Adults Older than 55 Years. <i>New England Journal of Medicine</i> , 2023, 388, 214-227.	13.9	62
2032	Microfluidics for nano-drug delivery systems: From fundamentals to industrialization. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3277-3299.	5.7	10
2033	COVID-19 vaccination among different types of US Healthcare Personnel. <i>Vaccine</i> , 2023, 41, 1471-1479.	1.7	5
2034	Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study. <i>Journal of Infection</i> , 2023, 86, e144-e147.	1.7	7
2035	Severity of COVID-19 among Residents in Aged Care Facilities in Victoria, Australia: A Retrospective Cohort Study Comparing the Delta and Omicron Epidemic Periods. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 434-440.e5.	1.2	0
2037	A 14-Day Therapeutic Exercise Telerehabilitation Protocol of Physiotherapy Is Effective in Non-Hospitalized Post-COVID-19 Conditions: A Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 776.	1.0	4
2038	Comparison of COVID-19 Severity in Vaccinated and Unvaccinated Patients during the Delta and Omicron Wave of the Pandemic in a Romanian Tertiary Infectious Diseases Hospital. <i>Healthcare (Switzerland)</i> , 2023, 11, 373.	1.0	5
2040	Covid-19 Vaccine Efficacy: Accuracy Assessment, Comparison, and Caveats. <i>Journal of Data Science</i> , 2024, , 45-55.	0.5	0
2041	Saving the Tree for the Forest: Lessons from Pandemics for Postcolonial Indigeneity in South Africa. , 2023, , 257-284.		0
2042	Omicron Infections in Otolaryngology Practice: A Retrospective Observational Study on Testing, Symptoms and Vaccination Status. <i>Advances in Infectious Diseases</i> , 2023, 13, 81-95.	0.0	0
2043	An integrated chance constraints approach for optimal vaccination strategies under uncertainty for COVID-19. <i>Socio-Economic Planning Sciences</i> , 2023, 87, 101547.	2.5	2
2044	Antiâ€“SARSâ€“CoVâ€“2 spike immunoglobulinâ€“ and immunoglobulinâ€“M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients. <i>Clinical Respiratory Journal</i> , 0, , .	0.6	0
2046	Scalable Inhibitors of the Nsp3â€“Nsp4 Coupling in SARS-CoV-2. <i>ACS Omega</i> , 2023, 8, 5349-5360.	1.6	4
2047	Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19â€“Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults â€“ VISION Network, Nine States, Septemberâ€“November 2022. <i>Morbidity and Mortality Weekly Report</i> , 2023, 71, 1637-1646.	9.0	30
2048	The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China. <i>BMC Public Health</i> , 2023, 23, .	1.2	1
2049	Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
2050	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	4
2051	Physical and mental health of breast cancer patients and survivors before and during successive SARS-CoV-2-infection waves. <i>Quality of Life Research</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
2052	COVID-19 outbreak in a religious village community in South Korea and risk factors for transmission. <i>Osong Public Health and Research Perspectives</i> , 0, , .	0.7	0
2053	Immunogenic fusion proteins induce neutralizing SARS-CoV-2 antibodies in the serum and milk of sheep. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 38, e00791.	2.1	2
2054	Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.	6.0	10
2055	Acceptance or rejection of vaccination against influenza and SARS-CoV2 viruses among primary care professionals in Central Catalonia. A cross-sectional study. <i>Vaccine: X</i> , 2023, 14, 100290.	0.9	1
2056	Analysis of the COVID-19 pandemic using a compartmental model with time-varying parameters fitted by a genetic algorithm. <i>Expert Systems With Applications</i> , 2023, 224, 120034.	4.4	7
2058	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
2059	Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48Âh post infection. <i>Journal of Theoretical Biology</i> , 2023, 565, 111470.	0.8	5
2060	Impact of Vaccination on Cost and Course of Hospitalization Associated with COVID-19 Infection. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2023, 3, .	0.2	1
2061	Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. <i>American Journal of Epidemiology</i> , 2023, 192, 895-907.	1.6	6
2062	Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study. <i>Vaccines</i> , 2023, 11, 297.	2.1	0
2063	Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2024, 42, 187-194.	0.2	3
2064	The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 95.	0.9	3
2065	Real-world performance of SARS-Cov-2 serology tests in the United States, 2020. <i>PLoS ONE</i> , 2023, 18, e0279956.	1.1	0
2066	COVID-19 therapy and vaccination: a clinical narrative review. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	10
2067	Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. <i>Nature Communications</i> , 2023, 14, .	5.8	14
2068	Venous or arterial thrombosis in COVID-19 cases in the North Carolina COVID-19 Community Research Partnership (NC-CCRP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100080.	1.0	3
2069	Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study. <i>Lancet Public Health, The</i> , 2023, 8, e174-e183.	4.7	8
2070	Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. <i>International Journal of Infectious Diseases</i> , 2023, 129, 188-196.	1.5	10

#	ARTICLE	IF	CITATIONS
2071	A Statistical Synopsis of COVID-19 Components and Descriptive Analysis of Their Socio-Economic and Healthcare Aspects in Bangladesh Perspective. <i>Journal of Environmental and Public Health</i> , 2023, 2023, 1-20.	0.4	1
2072	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1
2073	Mass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices. <i>Applied Materials Today</i> , 2023, 31, 101754.	2.3	7
2074	“Community members have more impact on their neighbors than celebrities” leveraging community partnerships to build COVID-19 vaccine confidence. <i>BMC Public Health</i> , 2023, 23, .	1.2	6
2075	COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. <i>Journal of Epidemiology and Global Health</i> , 2023, 13, 67-90.	1.1	3
2076	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
2077	A Synthetic Biology Approach for Vaccine Candidate Design against Delta Strain of SARS-CoV-2 Revealed Disruption of Favored Codon Pair as a Better Strategy over Using Rare Codons. <i>Vaccines</i> , 2023, 11, 487.	2.1	6
2078	Causal Inference of Central Nervous System-Regulated Hormones in COVID-19: A Bidirectional Two-Sample Mendelian Randomization Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1681.	1.0	2
2079	The COVID-19 Vaccination Coverage in ICU Patients with Severe COVID-19 Infection in a Country with Low Vaccination Coverage—A National Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 1749.	1.0	2
2080	Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Inveillance Study. <i>Journal of Medical Internet Research</i> , 0, 25, e45419.	2.1	1
2082	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
2083	mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!. <i>Vaccines</i> , 2023, 11, 507.	2.1	11
2084	Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. <i>Wellcome Open Research</i> , 0, 8, 96.	0.9	0
2085	Community purchases of antimicrobials during the COVID-19 pandemic in Uganda: An increased risk for antimicrobial resistance. <i>PLOS Global Public Health</i> , 2023, 3, e0001579.	0.5	5
2086	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
2087	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
2088	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
2089	Telepharmacy during home isolation: drug-related problems and pharmaceutical care in COVID-19 patients receiving antiviral therapy in Thailand. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	1.1	2

#	ARTICLE	IF	CITATIONS
2090	BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. <i>PLoS Pathogens</i> , 2023, 19, e1011196.	2.1	6
2091	Economic Analysis of Border Control Policies during COVID-19 Pandemic: A Modelling Study to Inform Cross-Border Travel Policy between Singapore and Thailand. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4011.	1.2	2
2092	Effectiveness of Inactivated Vaccine against SARS-CoV-2 Delta Variant Infection in Xiamen, China—A Test-Negative Case-Control Study. <i>Vaccines</i> , 2023, 11, 532.	2.1	0
2093	Age distribution and disease severity of COVID-19 patients continued to change in a time-dependent manner from May 2021 to April 2022 in the regional core hospital in Japan. <i>Drug Discoveries and Therapeutics</i> , 2023, 17, 60-65.	0.6	2
2094	Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines. <i>Vaccines</i> , 2023, 11, 544.	2.1	0
2095	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 545.	2.1	3
2096	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
2097	SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. <i>EFSA Journal</i> , 2023, 21, .	0.9	16
2098	An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. <i>International Immunopharmacology</i> , 2023, 117, 109934.	1.7	9
2099	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
2100	Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19. <i>BMC Medicine</i> , 2023, 21, .	2.3	3
2101	Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study. <i>Vaccines</i> , 2023, 11, 566.	2.1	3
2102	Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. <i>Annals of Medicine</i> , 2023, 55, 419-427.	1.5	4
2103	The Effectiveness of Covid-19 Vaccination in Indonesian Population: A Case-Control Study Protocol. , 2023, , 785-795.		0
2104	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
2105	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
2107	Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras. <i>Research</i> , 2023, 6, .	2.8	0
2108	Tracking Changes in Mobility Before and After the First SARS-CoV-2 Vaccination Using Global Positioning System Data in England and Wales (Virus Watch): Prospective Observational Community Cohort Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e38072.	1.2	0

#	ARTICLE	IF	CITATIONS
2109	The infected and the affected: A longitudinal study of the impact of the COVID-19 pandemic on schoolchildren in Florida. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	1
2110	In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5120.	1.8	2
2112	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
2113	5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 578-584.	0.0	0
2114	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4796.	1.2	2
2115	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. <i>BMC Clinical Pathology</i> , 2023, 16, 2632010X2311612.	0.7	3
2116	The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100465.	1.5	6
2117	Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers. <i>Vaccines</i> , 2023, 11, 626.	2.1	0
2118	Relationship Between Coronavirus Disease 2019 Vaccination Rates and Rare But Potentially Fatal Adverse Events: A Regression Discontinuity Analysis of Western Countries. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
2119	Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	18
2120	Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. <i>Expert Review of Vaccines</i> , 2023, 22, 341-365.	2.0	4
2121	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
2122	Immune responses of different COVID-19 vaccination strategies by analyzing single-cell RNA sequencing data from multiple tissues using machine learning methods. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
2123	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
2124	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
2125	Genome surveillance of SARS-CoV-2 variants and their role in pathogenesis focusing on second wave of COVID-19 in India. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2126	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2
2127	Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants. <i>Genome Biology and Evolution</i> , 2023, 15, .	1.1	1

#	ARTICLE	IF	CITATIONS
2128	The influence of single-point mutation D614G on the binding process between human angiotensin-converting enzyme 2 and the SARS-CoV-2 spike protein-an atomistic simulation study. RSC Advances, 2023, 13, 9800-9810.	1.7	0
2129	Delta Variant of Covid-19 and Hearing Loss. Indian Journal of Otolaryngology and Head and Neck Surgery, 2023, 75, 2634-2636.	0.3	1
2131	Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. Diagnostics, 2023, 13, 1280.	1.3	0
2132	Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study. Vaccine, 2023, 41, 3556-3563.	1.7	7
2133	Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2023, 18, e0272826.	1.1	7
2134	Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine, 2023, 90, 104545.	2.7	17
2135	Interferon-lambda: New functions on intestinal symptoms in COVID-19. World Journal of Gastroenterology, 0, 29, 1942-1954.	1.4	2
2136	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Vaccine, 2023, 41, 3003-3010.	1.7	1
2137	Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). Biology, 2023, 12, 519.	1.3	4
2138	Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. British Journal of Haematology, 2023, 201, 813-823.	1.2	7
2139	Insertion and deletion mutations preserved in SARS-CoV-2 variants. Archives of Microbiology, 2023, 205, .	1.0	2
2140	Perceived Norms and Vaccination against COVID-19 among the General Adult Population in Germany: Results of a Nationally Representative Survey. Vaccines, 2023, 11, 800.	2.1	0
2141	Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation: Cardiovascular Quality and Outcomes, 2023, 16, .	0.9	2
2142	Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study. Lancet Microbe, The, 2023, 4, e397-e408.	3.4	18
2143	Immunology of COVID-19. , 2024, , 52-71.		0
2144	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
2145	Association between the COVID-19 Vaccine and Preventive Behaviors: Panel Data Analysis from Japan. Vaccines, 2023, 11, 810.	2.1	1
2146	Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases. Rheumatology International, 2023, 43, 1033-1039.	1.5	3

#	ARTICLE	IF	CITATIONS
2147	The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
2148	HEALTHCARE SUPPLY AND DEMAND IN OECD COUNTRIES: CASE PRACTICE. <i>Å°stanbul Ticaret Åœeniversitesi Dergisi</i> , 0, , .	0.4	0
2149	Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7292.	1.8	2
2150	Drivers of SARS-CoV-2 testing behaviour: a modelling study using nationwide testing data in England. <i>Nature Communications</i> , 2023, 14, .	5.8	3
2151	SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants. <i>Journal of Clinical Immunology</i> , 0, , .	2.0	1
2152	Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients. <i>Current Stem Cell Research and Therapy</i> , 2024, 19, 644-652.	0.6	2
2153	The compound risk of heat and COVID-19 in New York City: riskscape, physical and social factors, and interventions. <i>Local Environment</i> , 0, , 1-29.	1.1	0
2154	Quality of life in patients treated for COVID-19-associated mucormycosis at a tertiary care hospital. <i>Osong Public Health and Research Perspectives</i> , 0, , .	0.7	0
2155	Assessing the Impact of Vaccination on the Dynamics of COVID-19 in Africa: A Mathematical Modeling Study. <i>Vaccines</i> , 2023, 11, 857.	2.1	1
2156	Ayurvedic medicines in alleviating the symptoms of SARS-CoV-2 omicron variant in North Indian population: a regional genomic study. <i>Drug Metabolism and Personalized Therapy</i> , 2023, 38, 289-291.	0.3	3
2157	Variant-specific introduction and dispersal dynamics of SARS-CoV-2 in New York City â€œ from Alpha to Omicron. <i>PLoS Pathogens</i> , 2023, 19, e1011348.	2.1	3
2158	Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022. <i>Medical Science Monitor</i> , 0, 29, .	0.5	0
2159	A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. <i>PLoS Pathogens</i> , 2023, 19, e1011298.	2.1	5
2160	COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative caseâ€œcontrol study with SARS-CoV-2 genetic sequencing. <i>BMJ Open</i> , 2023, 13, e068334.	0.8	0
2161	Immune Imprinting and Implications for COVID-19. <i>Vaccines</i> , 2023, 11, 875.	2.1	10
2165	Analysis of Genetic Characterization and Phylogenetic of SARS-CoV-2 from Manokwari West Papua. , 2023, , 221-233.		0
2176	A Syndemics Approach to NCAA Collegiate Sport Participation During COVID-19. , 2023, , 569-596.		0
2182	Metabolic Behavior of Covid-19 Infection Severity. , 2023, , 113-131.		0

#	ARTICLE	IF	CITATIONS
2195	Lessons Learned: Measurement of the Impact of Covid-19 Post-pandemic. Communications in Computer and Information Science, 2023, , 311-327.	0.4	0
2251	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
2311	Implementation of Vaccination in an Epidemic Model for COVID-19. Studies in Computational Intelligence, 2023, , 227-245.	0.7	0
2321	Molecular and serological testing in the setting of a global pandemic. , 2024, , 199-216.		0
2338	2020: The Triumph of Anti-Covid mRNA Vaccines. , 2023, , 155-173.		0
2356	Innovation-driven trend shaping COVID-19 vaccine development in China. Frontiers of Medicine, 2023, 17, 1096-1116.	1.5	0
2368	Detection of Novel COVID-19 Variants with Zero-Shot Learning. , 2023, , .		0
2375	Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis. Journal of Neurology, 2024, 271, 1063-1071.	1.8	0